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Abstract 
Background: Inactivation of wild type P53 by its main cellular inhibitors, MDM2 and MDMX, 
is a well-recognised feature of tumour formation in liposarcomas (LS). MDM2 over-
expression has been detected in approximately 80% of liposarcomas, but only limited 
information is available about MDMX expression levels. On commencing this work, we were 
not aware of any study that had described the patterns of MDM2 and MDMX co-expression 
in liposarcomas. Such information has become more pertinent as various novel MDM2 and / 
or MDMX single and dual affinity antagonist compounds have emerged as alternative 
approaches for potential targeted therapeutic strategies in LS. 
Methods: After appropriate optimisation and confirmation of experimental techniques, a 
case series of 64 pathologically characterised liposarcomas of various sub-types was 
analysed by immunohistochemistry, to simultaneously assess the expression levels of P53, 
MDM2 and MDMX. P53 mutation status was investigated in cases that over-expressed P53.  
Results: 83% of cases over-expressed MDM2 and 69% co-expressed MDMX at varying 
relative levels. The relative expression levels of the two proteins with respect to each other 
were subtype-dependent. This apparently affected the detected levels of P53 directly, in 
two distinct patterns. Diminished levels of P53 were observed when MDM2 was significantly 
higher in relation to MDMX, suggesting a dominant role for MDM2 in the degradation of 
P53. Higher levels of P53 were noted with increasing MDMX levels, suggesting an 
interaction between MDM2 and MDMX that resulted in reduced efficiency of MDM2 when 
degrading P53. No increased incidence of P53 mutations was detected in cases that over-
expressed P53 compared to the general population of LSs. 
Conclusions: The results of the study indicated that complex dynamic interactions between 
MDM2 and MDMX proteins may directly affect the cellular levels of P53 in human 
liposarcomas. This suggests that careful characterisation of all these markers will be 
necessary when considering in vivo evaluation of novel MDM blocking compounds as a 
therapeutic strategy to restore wild type P53 functions. 
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 1 
1 Introduction 
1.1 Soft Tissue Sarcoma 
Soft Tissue Sarcomas (STSs) represent an heterogeneous group of mesenchymal tumours 
from various tissues of origin, which display a spectrum of distributions across age groups. 
These relatively rare tumours account for 1% of all cancers in adults (1), with an estimated 
UK incidence of 3000 cases per year according to the database of Sarcoma UK and the 
National Cancer Intelligence Network (NCIN) (2). 
STS can arise at nearly any anatomical location. Their presentation and clinical behaviour 
depend largely on the type, site, size and the organs involved or in close proximity to the 
tumour. 
STSs are morphologically classified into 21 major types and 104 categorical subtypes 
according to the World Health Organisation (WHO) classification agreed in 2006 (3). Such 
classification may be confusing to many clinicians and may also fail to truly reflect their 
clinical behaviour, prognosis, molecular changes or response to therapy. Additionally, 
histological features can be deceptive and frequently very challenging for pathologists to 
base an accurate diagnosis upon. Unfortunately, traditional immunohistochemical markers 
of differentiation may be of little use in refining the diagnosis. 
In more recent years, a different approach to STS classification has attracted increasing 
popularity (4). This classification is based on the molecular and genetic alterations 
associated with sarcomas. It is mainly separated into two distinct categories: (1) STS with 
specific genetic alterations; and (2) STS displaying multiple, complex karyotypic 
abnormalities (5). This approach has provided a refreshing insight into the molecular 
mechanisms of sarcoma pathogenesis and has illustrated new relationships between 
different subtypes of STSs. Moreover, with the rise of non-traditional, targeted therapies for 
cancers in general and for sarcomas in particular, such classification may provide a more 
meaningful toolkit towards guiding a selective therapeutic approach. This methodology has 
influenced the most recent WHO classification of STSs, which was published in 2013 (6). The 
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new classification has incorporated some of the molecular and cytogenetic alterations as 
identifiable characteristic features. However, the traditional classification remains largely as 
the dominant approach (7). 
The mainstay of treatment for the majority of localized STSs is radical surgical excision with 
adequate, generous, excision margins (8, 9). The use of adjuvant radiotherapy is adopted in 
intermediate and high grade tumours, or when complete excision is not feasible (10). The 
recurrence rate of STS is variable but is largely dependent on the surgical resection margin 
status (8, 11). Recurrences are therefore low in sites where a wide compartmental excision 
is possible. However, in sites such as the retroperitoneum, obtaining a clear margin 
(particularly, the posterior margin) is difficult due to the anatomical constraints (12). In such 
instances the recurrence rates are significantly higher. Other factors influencing recurrence 
rates include histological subtype, use of adjuvant radiotherapy, and tumour size and grade. 
Recurrence rates may range between 5 – 75% depending on these factors and the level of 
expertise in the treating centre (13). 
It is estimated that half of all intermediate and high grade STSs in the UK develop metastatic 
disease eventually (2, 8). Patients with locally advanced and / or metastatic STS disease have 
few effective treatment options. Chemotherapy has an unproven role in the neo-adjuvant 
setting but is used in advanced, inoperable and recurrent cases, but with no convincing 
evidence of significant improvement in survival rates (14). 
The overall five-year survival of STS is approximately 60%. This has remained unchanged 
over the past 15 years (15). 
1.2 Liposarcoma 
Liposarcoma (LS) is a malignant neoplasm of the adipose tissue. It is the most common STS 
in adult life, accounting for approximately 20% of cases (16). The NCIN reported 6370 new 
LS cases in England between 1985 and 2009 with an age standardised incidence rate of 6 
per million population in the year 2009 (2). LS mainly presents after the age of 50 with a 
slightly higher incidence in males (17).  
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LS usually arise from deep-seated and well-vascularised structures rather than from 
submucosae or subcutaneous fat (18). Like most types of STS, LS may present in almost any 
anatomical location. However, in comparison to other STSs, they have a relative predilection 
for the trunk and the retroperitoneum (16). 
LSs present clinically as slow growing, asymptomatic soft tumours that eventually cause 
symptoms from gradual pressure on neighbouring organs. Therefore, they usually have a 
much delayed presentation, especially when they arise in anatomical cavities, partly due to 
the lack of striking presenting symptoms but also due to lack of awareness of this diagnosis 
amongst General Practitioners. 
In general, LS has a favourable prognosis compared with the other types of STSs with a 
median survival of 40 months (19). However, all STSs, including LS, presenting in the trunk 
and retroperitoneum have a poorer prognosis with a median survival of 21 months and a 
five year survival of 22.5% (19). This may largely be explained by the limitations in achieving 
satisfactory clear surgical resection margins. 
1.2.1 Liposarcoma Subtypes 
LSs are morphologically classified into four main subgroups: well-differentiated (WDLS); de-
differentiated (DDLS); myxoid - round cell (MXLS-RCLS); and pleomorphic (PLS). These major 
subtypes are not only histologically distinct but they also have distinctive cytogenetic and 
molecular signatures. Consequently, they demonstrate different clinical behaviours and 
prognosis.  
1.2.2 Well-Differentiated Liposarcoma 
Accounting for 40% of cases, WDLS is the most common subtype of LS (6, 20). It is also 
known as an “atypical lipomatous tumour” when it presents in a relatively superficial tissue 
plane. These tumours look deceptively similar to benign lipomas and the distinction 
between the two can frequently be challenging for pathologists. They demonstrate a 
characteristic feature of scattered lipoblasts with atypical hyperchromatic nuclei of variable 
sizes and shapes (6). 
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WDLS is considered as a low grade neoplasm. It rarely metastasises and has a low 
recurrence rate given adequate excision. However, it is known to be resistant to 
conventional chemotherapy (21).  
1.2.2.1 De-Differentiated Liposarcoma  
Morphologically, DDLS has cellular features similar to WDLS, with associated features of 
non-lipogenic sarcoma of high or low grade. The presence of a transition from WDLS to 
DDLS is used as a histological diagnostic feature (22).  Clinically, DDLS is a more aggressive 
tumour compared to WDLS, with a higher tendency to arise in the retroperitoneum and to 
proliferate rapidly (18). The recurrence rates of DDLS in the retroperitoneum approach 75%, 
the metastatic rate is 10-20% and overall 5 year mortality is 50-75% (14). Similar to WDLS, 
DDLS are also resistant to chemotherapy (21). 
1.2.2.2 Myxoid - Round Cell Liposarcoma  
MXLS is the second most common subtype of LS accounting for a third of cases. 
Histologically, MXLS features an abundance of extracellular matrix, with the presence of 
spindle or ovoid cells. Signet ring lipoblasts and “chicken-wire” vascular arcades are 
pathognomonic. RCLS de-differentiation produces a similar appearance but with areas of 
greater cellularity (23). 
These tumours are usually smaller in size but are more aggressive, with a higher metastatic 
rate (17%). 65% of these metastases occur in the skeleton with a 15% 5 year survival from 
time of first metastasis (24). MXLSs without the de-differentiated RCLS component are 
particularly radiosensitive in both the adjuvant and the neo-adjuvant settings (25). 
1.2.2.3 Pleomorphic Liposarcoma  
Accounting for 5% of LS, PLS is the rarest and most aggressive subtype. It has a tendency to 
arise from deep structures within the lower or upper extremities (26). The histological 
appearance of PLS is of high grade aggressive sarcoma showing disorderly growth patterns, 
extreme cellularity and bizarre giant cells. They are frequently identified by the presence of 
distinctive lipoblasts having multiple, small, intra-cytoplasmic fat vacuoles (27). 
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Approximately 45% of cases return with local recurrence and /or metastasis within 3 years 
of initial surgical treatment. The 5 year mortality rate is 50% in focal, non-metastatic disease 
at time of diagnosis (28). 
1.2.3 Molecular Classification of Liposarcomas 
Gene expression profiling of LS has introduced a new integral methodology into the WHO 
classification (29). Based on this classification, LS can generally be clustered into three main 
groups: LS with amplification of chromosomal regions; LS with specific chromosomal 
translocation(s); and LS with complex genetic alterations. 
1.2.3.1 Liposarcomas with Gene Amplification  
The presence of supernumerary ring or giant rod chromosomes is a characteristic feature of 
WDLS and DDLS. These chromosomes contain amplified segments from the 12q13-15 region 
(30-32). 
The presence of amplified chromosomal segments can be detected by fluorescence in situ 
hybridisation (FISH) and comparative genomic hybridisation (CGH) (31).  Consequently, 
analysing LS by FISH has become a standard routine diagnostic procedure. The Pathology 
Department at Leeds Teaching Hospitals NHS Trust (LTHT) has incorporated this analysis into 
its diagnostic protocols since 2009. 
Research has identified various oncogenes encoded in this amplified region including 
MDM2, CDK4, HMGA2 and TSPAN31. MDM2 “the murine double minute 2” is a negative 
regulator of the tumour suppressor P53. It is amplified in nearly 100% of WDLS and DDLS 
and CDK4 is amplified in 90% of these subtypes. Co-amplification of MDM2 and CDK4 is well 
reported (33). 
Whereas FISH analysis has proved to be a valuable diagnostic tool to differentiate between 
WD/DDLS and benign lipomatous tumours, with high sensitivity and specificity, it does not 
distinguish WDLS from DDLS (20, 34). 
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1.2.3.2 Liposarcomas with Chromosomal Translocations   
MXLS - RCLS are characterised by the recurrent translocation of the FUS and CHOP (also 
known as DDIT3) genes resulting in a t(12;16)(q13;p11) rearrangement in 95% of cases (35). 
A less common translocation between the CHOP and EWS genes resulting in a 
t(12;22)(q13;p12) rearrangement has also been reported (36). A significant body of evidence 
suggests that these translocations are the primary oncogenic event in MXLS-RCLS, as these 
tumours otherwise frequently retain a relatively normal karyotype. 
1.2.3.3  Liposarcomas with Complex Genetic Alterations  
PLS are reported to display an array of complex genomic imbalances, including multiple 
chromosome duplications, deletions and complex rearrangements, polyploidy and 
intercellular heterogeneity. These cytogenetic alterations more closely resemble those of 
other pleomorphic sarcomas than those of other subtypes of LS. However, due to the rarity 
of the disease, descriptive molecular studies of this subtype are confined to a limited 
number of cases (37). 
The characteristic histological and molecular features of LS subtypes are summarised in 
Table 1.1. 
1.3 P53 
The P53 protein was first described as a transformation-related protein in chemically-
induced sarcomas and other murine cancers, in 1979 (38). P53 was initially thought to 
possess weak oncogenic activity, due to an initial misconception of its mutant profile as wild 
type (wt). It was not until 10 years later that researchers identified the actual wt sequence 
of P53 and started to describe its significant spectrum of mutations in human cancers (39). 
P53 knockout mouse experiments in the 1990s provided unquestionable evidence in 
support of the potent tumour suppressor role of wt P53 (40). Subsequently, P53 has 
become the most common site of known genetic alterations in human cancers (41).  
It is known that approximately 50% of cancers have acquired inactivating mutations / 
deletions of P53 (42). However, the incidence of P53 mutations in STS had been reported to 
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be significantly lower, and previous analyses have estimated that only 17% of LSs have a 
somatic P53 mutation (43, 44). In cancers where the wt status of P53 is retained, its 
functions are often found to be compromised by other mechanisms. These include nuclear 
exclusion, interaction with viral proteins or, more frequently, by its main cellular inhibitors 
such as MDM2 protein (45). 
Germline autosomal dominant mutations of P53 are the molecular basis of the earlier-
described familial cancer syndrome, currently known as Li-Fraumeni syndrome (46, 47). A 
recent review that utilised the International Agency for Research on Cancer (IARC) database 
and included 531 independent families or individuals with Li-Fraumeni syndrome has shown 
that STSs claimed 25% of cancers in these patients at different ages of onset (48). 
In addition to its own biochemical functions, P53 exerts numerous effects through its ability 
to activate multiple specific target genes. Therefore, P53 is seen as a key regulator of the 
cell cycle, apoptosis, DNA repair, development, differentiation, chromosomal segregation 
and cellular senescence (49).  
P53 belongs to a specific protein family that also includes P63 and P73. These proteins are 
structurally and functionally related. However, P53 has evolved in higher organisms to 
prevent carcinogenesis, whereas P63 and P73 have well characterised roles in normal cell 
biology (50). 
It is known that non-sarcomatous malignancies with wild type P53 usually demonstrate a 
clinical pattern that is more responsive to chemotherapy and radiotherapy (43). This 
response is not seen in STS, probably due to the lack of targeted therapies against specific 
pathways of particular significance in their development. The best characterised pathway of 
this type is the interaction of wild type P53 with the MDM2 and its homolog “murine double 
minute X” (MDMX) proteins (51). 
1.3.1 P53 Structure 
Human P53 is mapped to the short arm of chromosome 17 (17p13.1). Encoded by a 20 kb 
gene, it contains 11 exons and 10 introns (52). Wt P53 protein is comprised of 393 amino 
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acids and has a molecular weight of 53 kDa. It is composed of the following three structural 
and functional domains (Figure 1.1): 
N- terminus (residues 1-94): contains an amino-terminal domain at residues 1-42, 
responsible for transactivation activity and interaction with transcription factors including 
MDM proteins. It also has a proline-rich region (residues 61-94), which plays a major role in 
P53 stability, making it more susceptible to degradation mediated by MDM2 if this region is 
deleted (53). 
Acidic central core domain (residues 102-292): This is primarily the sequence-specific DNA 
binding domain. The majority of P53 missense mutations are located within this domain. In 
fact, more than 80% of research that described P53 mutations in cancer has focused on 
residues between 126 and 306 (54).  
C –terminus (residues 292-393): This contains a nuclear localisation signal, a tetramerisation 
domain (residues 324-355), 3 nuclear export signals and a regulatory domain (residues 363-
393). The C-terminus influences the efficiency of P53 when acting as a transcription factor. 
Unlike many other transcription factors, P53 has a second DNA binding domain which maps 
to its C-terminus (55). 
P53 expresses up to ten different isoforms via alternative promoters, alternative splicing 
sites and alternative translation initiation sites. Most of these isoforms retain the central 
core region containing the DNA-binding domain. Recent reports suggest that some of these 
isoforms may act functionally as P53 antagonists (56, 57). The detailed assessment of P53 
isoforms’ expression in cancers may provide a better understanding of their roles in tumour 
formation. 
1.3.2 Relevant P53 Functions 
Wild type P53 may be activated in response to numerous genotoxic stressors including DNA 
damage, oncogenic activation, hypoxia, heat shock, viral infection, ultraviolet radiation and 
cytotoxic drugs (45). It exerts most of its functions through its ability to act as a sequence-
specific transcription factor regulating the expression of various target genes to modulate a 
spectrum of cellular responses. These target genes are functionally diverse and mediate an 
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array of downstream cellular outcomes including cell-cycle checkpoints, cell survival, 
apoptosis and other metabolic processes. The extent of these cellular activities is very 
dynamic and largely dependent on the cell type, the extent of damage and other 
unidentified parameters (58).  
Thirty years of extensive research has identified hundreds of P53 responsive genes. Some of 
the most extensively characterised of these are: CDKN1A and MIR34A for cell cycle arrest; 
CDKN1A and PAI1 for senescence; PUMA and BAX for apoptosis; and TIGAR, SCO2 and GLS2 
for metabolic processes (59). 
An abridged summary of the most relevant pathways is included below. However, 
comprehensive narrative accounts of P53 functions and pathways can be found in several 
published reviews (59-61). 
1.3.2.1 Cell Cycle Regulation  
The ability of P53 to induce cell cycle arrest is pivotal to its tumour suppressor function, as 
this provides additional time for the cell to repair genomic damage before entering the 
critical DNA synthesis phase. P53 can induce cell cycle arrest in G1 phase through activating 
the cyclin- dependent kinase (CDK) inhibitor and / or p21
waf1/Cip1
, which may be the best 
known downstream targets of P53 (62). P53 can also induce cell cycle arrest in G2 and S 
phases via other downstream targets like GADD45 and 14-3-3δ (63). 
1.3.2.2 Apoptosis  
P53 can induce apoptosis in response to severe or irreversible cellular damage. This is 
mainly achieved via two distinct mechanisms: Intrinsic Pathway where mitochondrial 
depolarisation takes place activating caspase 9 to induce apoptosis (64); and Extrinsic 
Pathway where expression of cell death receptors increases and inhibition of production of 
IAPs (inhibitor of apoptosis proteins) takes place, resulting in activation of caspase 8 and 
cellular death (65). 
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It has been shown that loss of P53-dependent apoptosis induces brain cancer in the mouse, 
confirming the correlation between this particular function of P53 and its ability to suppress 
malignant transformation (66). 
1.3.3 Cellular Regulators of P53 
It is not surprising that P53 is heavily regulated by a complex network of cellular proteins, 
bearing in mind its role in maintaining integrity of the cell and inducing apoptosis. Under 
normal conditions, wt P53 half-life is limited to minutes and its expression is maintained at 
low concentrations in a latent, inactive form (61). When cellular stress occurs, increased P53 
levels are seen primarily as a result of an increase in its half-life to hours (67). 
Numerous different proteins are involved in P53 regulations including HPV16/E6 (68), WT-1 
(69), E1B/E4 (70),  JNK (71), PIRH2 (72) and PARP1 (73). The regulation takes place on 
multiple cellular levels including promotion of transcription, post-translational modification 
and rate of degradation. However, tight control of P53 levels is primarily achieved through 
ubiquitinylation-mediated proteasomal degradation by its main cellular inhibitor the MDM2 
(74). Mammalian cells also express an MDM2 homolog called MDMX (also known as 
MDM4), which is an equally important regulator of P53. A significant body of evidence 
suggests that MDMX is a negative regulator of P53, independent of MDM2 (75). 
Details of the regulatory interactions between P53, MDM2 and MDMX are discussed in 
Section 1.5 of this Chapter. The functional regulators of P53 have been comprehensively 
reviewed in recent publications (57, 76). 
1.4  MDM2 and MDMX 
1.4.1 Gene Amplification and Overexpression 
The human MDM2 and MDMX genes have been mapped to the chromosomal locations 
12q13-14 and 1q32, respectively (77, 78). MDM2 contains 12 exons and MDMX has 11. 
Whereas MDM2 amplification has been accepted as a characteristic feature in nearly 100% 
of WDLD / DDLS (79), MDMX amplification has been reported in only 17% of human LS (80). 
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Recent studies have also reported MDMX co-amplification with MDM2 in STS, and 
particularly in LS (81, 82). In addition to LS, amplification of MDM2 or MDMX has also been 
noted in other tumours including glioblastoma (83), cutaneous melanoma (84), 
osteosarcoma (81), oesophageal (85), colorectal (86) and breast cancer (87). 
Overexpression may or may not occur in conjunction with amplification of these genes (80, 
88). MDM2 overexpression was detected in approximately 75% of WDLS / DDLS subtypes by 
immunohistochemistry (89, 90). High levels of MDM2 mRNA have been reported as a 
negative prognostic factor in STS, including liposarcomas (91). It may be of particular 
significance to the studies described herein that the phenomenon of MDM2-mediated P53 
inactivation has a tendency to occur more often in retroperitoneal LS, compared to those 
that arise in the extremities (34). 
Work on established cancer cell lines has shown that the incidence of MDMX over-
expression is variable amongst different types of human cancers and seems to occur in 
between 20-40% of tumours, including STS (80, 92, 93). Overexpression of MDMX was also 
reported without either P53 mutations or MDM2 amplification, in glioblastomas (94). This 
observation supported the suggestion of an independent role for MDMX in the 
transformation process. It has been noted that the overexpression of MDM2 and / or 
MDMX in tumour cells generally correlates with retained wild type P53 (93, 95). 
1.4.2 Protein Structure 
The MDM2 and MDMX proteins share striking structural similarities. Their full length 
proteins are comprised of 491 and 490 amino acid residues, respectively (78). They have a 
similar predicted molecular weight of 56 kDa, with several conserved structural domains 
(Figure 1.2) including: 
N-terminal hydrophobic pocket: Both MDM2 and MDMX bind to P53 through this domain. 
There is approximately 50% amino acid sequence identity between the two MDM proteins 
in this domain (96). However, the small structural differences between the two proteins in 
this region have important implications for the design of blocking antagonists to prevent 
MDM / P53 interactions. DNA damage induces phosphorylation at the N-termini of both 
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MDM2 and MDMX, by damage-activated kinases, and is reported to disrupt MDM binding 
to P53 in vitro (97, 98). 
Central acidic domain: This region contains nuclear export and import signals, which are 
vital for proper nuclear-cytoplasmic trafficking of MDM2. Phosphorylation of this domain is 
again important for the regulation of function for both proteins. 
C-terminal domain:  The C-termini of MDM2 and MDMX have a rare C2H2C4 protein -
protein binding domain which consists of two RING domains (Really Interesting New Gene), 
while one of the RING domains has the classical 4 cysteine structure (C4), the other consists 
of 2 histidine and 2 cysteine residues binding the zinc atom (99). This RING domain is critical 
for the binding of the MDM2 / MDMX heterodimers to P53 leading to subsequent 
ubiquitinylation and degradation. Despite conservation of the RING domain in MDMX, it 
apparently lacks an intrinsic ubiquitin ligase activity towards P53 (100). 
1.4.3 Intracellular Localisation 
MDM2 is primarily a nuclear protein. However, many cell-line studies have reported 
abundant expression in the cytoplasm, suggesting cytoplasmic localisation might also be 
important for its function. This observation is not unexpected due to the presence of a 
nuclear export domain in MDM2, which has been reported to enhance P53 translocation 
from the nucleus to the cytoplasm, with MDMX possibly modulating this process (101). 
Since MDM2-mediated proteasomal degradation of P53 occurs in the cytoplasm, the ability 
of MDM2 to move to the cytoplasm may therefore be important in MDM2-mediated P53 
turnover (102). 
The intracellular localisation of MDMX varies between different cell lines, with some studies 
showing predominantly cytoplasmic localisation (103, 104). However, MDMX is translocated 
into the nucleus upon co-expression of MDM2 or P53 (104-106). Therefore, MDMX may 
depend on MDM2 for nuclear redistribution in order to deactivate P53. 
The cellular localisation of P53 is equally dynamic and correlates with many variables 
including cell cycle phase, mutational status, cancer cell type and interaction with other 
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proteins (107, 108). Uncontrolled cellular division due to loss of P53 functions is generally 
seen in cells with P53 localised predominantly in the cytoplasm. 
1.4.4 Splice Variants 
Multiple MDM2 and MDMX splice variants have been reported in the literature. Only the 
functional and the most common variants are discussed below. 
1.4.4.1 MDM2 Splice Variants  
Over 40 splice variants of MDM2 have been identified in both tumours and normal tissues 
(109, 110). In humans, MDM2-A and MDM2-B are the most common and potentially 
functional splice variants of MDM2. They were first identified in paediatric 
rhabdomyosarcomas in 2002 (111). However, the exact function(s) of these variants remain 
somewhat controversial and not yet fully understood (112). 
MDM2-A and MDM2-B are missing exons 4-9 and 4-11, respectively, from the full length 
MDM2 RNA. Consequently, their resulting protein isoforms lack the P53 binding domain 
(Figure 1.3). However, MDM2-A retains the central acidic and the carboxy-terminal RING 
finger domains, the latter being important for binding with other proteins as well as 
ubiquitinylating P53. 
Previous data suggested that both MDM2-A and MDM2-B isoforms interacted with full 
length MDM2 to sequester it in the cytoplasm, away from P53 (113). Therefore they may act 
like MDM2 inhibitors, blocking its anti-P53 activity (114). However, these data are not 
consistent with the frequent expression of these splice variants found in various tumours 
(115). 
Mdm2-A transgenic mouse models have been created to examine the effects of this isoform 
on P53 functions. P53-dependent death in-utero was observed in the Mdm2-A homozygous 
group. Growth inhibition, enhanced senescence and accelerated aging were demonstrated 
in the Mdm2-A heterozygous group, with some of these effects occurring in a P53-
dependent manner (112). These findings could indicate that Mdm2-A expression may 
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protect against cancer formation through enhanced P53 activity. However, further studies 
are needed to clarify the exact physiological effects of MDM2-A in human cells.  
More recent studies have described the MDM2-C splice variant as a functional oncogenic 
protein that is over-expressed in some human cancers (116). MDM2-C lacks amino acid 
residues corresponding to exon 5 through 9, which include part of the P53 binding domain 
and hence its functions may be P53-independent. 
1.4.4.2 MDMX Splice Variants  
Numerous splice variants of MDMX have been identified in a variety of murine and human 
tumour cell lines (117). The most extensively described of these is MDMX-S, characterised 
by loss of exon 6, which results in a frame shift and incorporation of 26 unique amino acids 
followed by a premature stop codon (see Figure 1.4). MDMX-S is the commonest splice 
variant in STS, detected in 14% of cases (80). A recent study has proposed that the MDMX-
S/MDMX ratio positively correlates with early metastasis and poor prognosis (118). Other 
functional MDMX splice variants have been described including MDMX-A, characterised by 
loss of exon 9 sequences encoding the acidic domain and MDMX-G, which lacks the P53 
binding domain (119). 
In contrast to MDM2, a major proportion of MDMX splice variants described in the 
literature are functional and  may even be more effective than full length MDMX in 
inhibiting P53-mediated induction of apoptosis (117, 119). An MDMX-L isoform with 18 
amino acid N-terminal extension has been reported as a potent promoter of P53 
degradation. This isoform is induced by P53 itself under specific circumstances (120). 
1.4.5 Relevant Single Nucleotide Polymorphisms 
Perhaps the most relevant P53 single nucleotide polymorphism (SNP) reported in STS is the 
replacement of arginine by proline at codon 72 (Arg72Pro, rs1042522). This polymorphism 
occurs in the proline-rich domain of P53 resulting in decreased apoptotic potential (121) and 
increased susceptibility to degradation by MDM2 (122). Interestingly, a recent report 
analysing 174 STS cases has reported the over-representation of Pro72 occurred mainly in LS 
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patients and particularly those with WDLS (>60%). The same study reported P53 mutations 
in only 6% of these cases (123). 
An MDM2 polymorphism, rs2279744, changes a base from T to G at position 309 in the 
MDM2 promoter resulting in higher levels of MDM2 RNA and protein, consequently 
attenuating P53 pathways both in vitro and in vivo. Homozygosity of the G allele is strongly 
associated with MDM2 amplification and is frequently seen in LS (81). 
No MDMX polymorphisms have been reported to be important in either the occurrence or 
progression of STS. However, a polymorphism replacing A with C at the 3’-untranslated 
region (3’-UTR) of MDMX, rs4245739, may contribute to breast cancer susceptibility (124) 
and may  have a prognostic role in other cancers including ovarian and retinoblastoma 
(125). 
1.5 P53 / MDM Interactions 
The P53 / MDM interactions are complex and multi-layered. Below is a brief summary of the 
most relevant of these interactions in the context of this study. 
1.5.1 Molecular Basis of the Interaction 
MDM2 and P53 regulate each other’s functions through an auto-regulatory feedback loop. 
When activated, P53 transcribes the MDM2 gene and, in turn, the MDM2 protein inhibits 
P53 activity (126). This inhibition is achieved by various mechanisms, but mainly through 
MDM2 binding to P53, shielding its N-terminus from recruitment of transcriptional 
activators (127), or by MDM2 acting as an ubiquitin E3 ligase targeting P53 for proteasomal 
degradation (128). Whereas activated P53 was thought to exclusively upregulate MDM2 
(128), recent data has also shown a P53-dependent increase in MDMX-L expression under 
specific cellular conditions (120). 
Similar to MDM2, MDMX binding to P53 occludes the N-terminal alpha helix of P53, which is 
essential for the recruitment of transcriptional co-activators. Therefore, this binding inhibits 
P53 transactivation functions (76). Generally, chains of poly-ubiquitinylation are needed to 
initiate protein degradation, whereas mono-ubiquitinylation modulates target protein 
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function. The MDM axis interactions with P53 are not an exception. In certain 
circumstances, mono-ubiquitinylation of P53 by MDM2 has been reported to modulate the 
function of p53, affecting transcription, DNA repair and its intracellular localisation (129-
131).  
In contrast to MDM2, MDMX alone does not mono-ubiquitinylate P53. Several study models 
have suggested that MDM2 / MDMX hetero-dimers recruit E2 ubiquitin-conjugating 
enzymes resulting in a more potent complex for P53 degradation when compared to MDM2 
homodimers (132, 133). No MDMX homodimers have been identified in vitro or in vivo, 
which may suggest that MDMX is monomeric (96). 
MDM2 and MDMX regulate one another through a series of dynamic interactions. MDM2 
has the ability to ubiquitinylate itself and MDMX in order to maintain the negative feedback 
loop (119, 134). However, this function may be limited and becomes futile beyond a certain 
threshold of activity (135). On the other hand, MDMX enhances the effect of MDM2 by 
increasing its relatively short cellular half-life and therefore promoting P53 degradation 
(136). Other studies, however, have suggested that MDMX may stabilise P53 and, in fact, 
antagonise the MDM2-targeted degradation of P53 (106, 137). 
It appears that the cellular levels of MDM2 and MDMX relative to one another, play an 
important role in their vibrant interactions. One report suggested that MDMX promotes 
MDM2 auto-ubiquitinylation when the latter exceeds a certain threshold of cellular 
abundance (100). The mutual dependence model described by Gu et al., in modified cell 
lines, suggested that the actual cellular functions of MDMX vary between activation and 
inhibition of MDM2, depending on their relative expression levels (105). This model may 
have provided an explanation for some of the controversies surrounding MDMX function in 
cell lines, in a relatively coherent manner. However, it lacks support from careful descriptive 
studies performed on actual human cancer tissue. 
Overall, the literature demonstrates that MDM2 and MDMX are proteins that compete with 
each other in complex patterns to bind to P53 in a process designed to maintain the critical 
correct level of P53 activity (138, 139). MDMX expression by cells is vital for efficient 
MDM2-mediated P53 degradation (140). However, the co- expression of MDMX has to be 
finely tuned in order to optimise this crucial function of MDM2. 
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1.5.1.1 Fine Tuning of the Interactions 
Additional layers of post-transcriptional modifications of MDM proteins have also been 
reported as fine tuning modulators of their interactions. For example, phosphorylation of 
MDM2 at Ser166 and Ser186 (141), and MDMX at Ser 367 (142) can lead to their 
stabilisation and therefore inhibition of P53. In response to genetic stress, DNA-dependent 
protein kinase (DNA-PK) phosphorylates Ser17 of MDM2 (97) and ABL phosphorylates Tyr99 
of MDMX (98) leading to dissociation of P53 from its negative regulators. 
The complex series of interactions between P53 and the MDM axis, also involves active 
participation of other proteins that regulate these pathways. Collectively, these interactions 
are responsible for maintaining the balance between cell viability and apoptosis. Although 
these interactions have been the focus of many studies, there continues to be a need for 
more research effort to fully understand the details of the mechanisms involved. Perhaps 
the most relevant of these interactions is that involving the Alternative Reading Frame 
protein (ARF) (143). ARF interacts with MDM2, blocking the shuttling of MDM2 between the 
nucleus and the cytoplasm, by sequestering it in the nucleolus. In effect, this prevents 
MDM2-mediated P53 degradation and so results in activation of P53 (144). ARF also 
promotes MDM2 ubiquitinylation of MDMX (135). On the other hand, overexpression of 
RAS proteins has been reported to upregulate both MDM2 and MDMX, leading to P53 
inhibition (145, 146). 
It is important to mention that both MDM proteins have been reported to have P53-
independent oncogenic activities through interacting with other downstream targets (147). 
For example, MDM2 inhibits the potent tumour suppressor retinoblastoma protein (RB) 
(148) and promotes proliferation through the formation of complexes with the 
transcriptional activators E2F/DP1, resulting in DNA synthesis (149). This may explain the 
reported cellular overexpression of MDM2 and MDMX in tumours that have a mutant P53 
profile. In turn, it may also explain the selection of mut P53 (and not only the wt P53) 
tumours for deregulation of MDM pathways. 
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1.5.2 Animal Models 
In vivo experiments have convincingly proven the importance of P53 / MDM axis 
interactions to maintain life. Mouse models lacking functional Mdm2 do not survive 
embryogenesis, but can be completely rescued by the elimination of P53 activity (150, 151), 
with similar observations noted in MdmX null mice (152). Neither Mdm2 nor MdmX loss 
could be compensated for by the presence of the other. This demonstrates that both 
proteins work collectively on the balance of P53 activity, but possibly via independent 
mechanisms. 
The synergistic affiliation of MDM2 and MDMX in inhibiting P53 was also observed during 
CNS development, in mouse models. Loss of Mdm2 activity in the CNS resulted in 
hydranencephaly at embryonic day 12, whereas MdmX deletion resulted in pronencephaly 
at embryonic day 17. Much earlier and more severe CNS phenotypes were seen when both 
Mdm2 and MdmX were deleted and all these phenotypes were rescued by associated 
deletion of P53. 
Other animal studies have also confirmed the critical role of the C-terminal RING domain of 
MDM2 and MDMX in inhibiting P53. Point mutation in MdmX disturbing its RING domain 
and its Mdm2 binding site for forming heterodimers was embryonically lethal in a P53-
dependent manner (153). Similar observations were found with matching Mdm2 point 
mutations (154). Collectively, these observations confirmed the vital interactions between 
the two MDM proteins to maintain a viable level of P53 activity. The regulatory effects of 
important phosphorylation sites in MDM2 to stabilise P53 in response to DNA damage were 
confirmed in mice models, bearing altered Mdm2 alleles. Substituting Serine by Alanine at 
the Mdm2 394 residue (S394A), prevented phosphorylation and consequently resulted in 
accelerated tumour formation (155). 
1.5.3 The Gaps in Current Knowledge 
Quantitative studies have proven that the relative nuclear abundance of MDM proteins in 
relation to P53 correlated with limiting P53 activity in culture-grown cells (51). However, 
only a few studies have described the simultaneous expression levels of MDM2 and MDMX 
proteins in cancer cells, their expression levels relative to each other and the possible 
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effects of this on P53 (87, 105). Furthermore, these studies were limited to cell lines and 
may not be applicable to actual cancer tissues. Such characterisation is pivotal to clarify the 
putative utility of novel, single and dual affinity MDM2/MDMX blocking compounds in the 
treatment of STS and other cancers. 
1.6 Potential Novel Therapeutic Strategies  
As approximately 50% of tumours retain a wt P53 that is presumed to be inhibited by 
interacting with MDM proteins, it is expected that targeting this interaction would be an 
attractive approach towards selective cancer treatment. However, as both MDM2 and 
MDMX are required for normal tissue functions, it is clearly challenging to provide maximal 
therapeutic benefit with minimal mechanism-based toxicity. In other words, the therapeutic 
index may be a narrow one. Targeting the P53-MDM interaction may be achieved in 
different ways including modulating MDM protein expression and targeting E3 ubiquitin 
ligase activity. However, the most promising and widely explored approach has been 
through inhibiting the various protein-protein interactions using selective antagonists. 
1.6.1 MDM2 Blockers 
Since the discovery of MDM2 and the recognition of its cellular functions, large libraries of 
small molecules have been screened using high throughput techniques in the search for 
targeted blockers. In addition, structure-based molecular design methods have been 
employed to yield three major groups of P53-MDM2 interaction inhibitors. These groups 
are: the Nutlins (156); the Benzodiazepinediones (157); and the Spiro-oxindoles (158).  
These sets of compounds bind to MDM2 with high affinity, disrupting the P53-MDM2 
interaction to re-establish wt P53 activity. Of these compounds the activity of Nutlin-3a is 
the best defined and studied. 
In vivo experiments with Nutlin-3a, have demonstrated selective activity against tumours 
that over-express MDM2 and retain wt P53, with very encouraging results (159). 
Furthermore, several studies have suggested that rational combinations of Nutlin-3a with 
other chemotherapeutic agents may potentiate their effects and perhaps protect normal 
cells from cytostatic agents (160). 
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The other most promising MDM2 antagonist compound, from the Spiro-oxindole family, is 
MI-219. MI-219 has a superior pharmacokinetic profile compared to Nutlin-3a. Both 
compounds have not shown visible toxicity in related animal studies (161, 162). 
Two orally active MDM antagonists have recently entered phase I clinical trials, RG7112 (a 
second generation of Nutlin-3a) from Hoffmann La Roche (Switzerland) and JNJ-26854165 
from Johnson and Johnson (USA). Some proof of mechanism of action, from clinical 
applications of RG7112 in LS patients, has recently been published, with potentially 
encouraging prospects (163). 
However, due to the low binding affinity of Nutlins to MDMX, they do not appear to disrupt 
P53-MDMX interactions (164, 165). Therefore, they are not effective in tumours selectively 
over-expressing MDMX. This observation has led to a search to identify and design 
compounds that do disrupt P53–MDMX complexes, with either a specific or dual MDM 
antagonist activity. 
1.6.2 MDMX Blockers 
The first specific MDMX antagonist compound was identified and characterised in 2010 
(166). SJ-172550 has significant affinity for MDMX, binding to it in a reversible manner. This 
compound has shown significant anti-cancer activity in retinoblastoma cells that over-
express MDMX. It also displayed a synergistic apoptotic effect when used with Nutlins. 
However, later studies have shown that this compound may be unstable in vivo and has a 
complex mechanism of action that involves covalent adduct formation in the P53-binding 
domain of both MDM2 and MDMX, which hinders its further development (167). 
The stabilised α-helix of p53 variant 8 (SAH-p53-8) is a new modified peptide antagonist to 
MDM2 and MDMX interactions with P53 (168). It has 25 fold greater affinity for MDMX 
compared to MDM2. Its structural modification has increased its in vivo stability and 
improved its cellular uptake (169). This has introduced an encouraging new approach in 
drug development as peptides can antagonise protein-protein interaction more efficiently 
due to their large interaction surfaces. 
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1.6.3 Dual Affinity Blockers 
Computational studies, Ensemble-based virtual screening technologies and phage display 
techniques have allowed the identification of compounds with comparable dual MDM2 and 
MDMX affinity (170-175). These studies provided proof-of-concept for the feasibility of joint 
MDM2 and MDMX blocking, introducing the first generation of dual specificity blocking 
compounds. Essentially, all MDM blockers have dual-affinity properties to some degree. 
However, finding an appropriate balance of affinities in a potent “druggable” compound 
would be a significant result in this area of research. 
These compounds have gone through patent review (176) and are progressing swiftly in the 
pre-clinical development phase to define and optimise their therapeutic properties. 
However, their activities on cancer tissue have not been reported. Should structure / activity 
optimisation of these compounds provide lead drugs, then employment of these in clinical 
trials would be an important novel step in targeted cancer management. 
1.6.4 Alternative P53 Activation Approaches 
Small molecules that inhibit MDM2 ubiquitin ligase activity have been identified including 
HLI98 (177) and MEL23, MEL24 (178). These compounds bind to MDM2 and P53, enhance 
their stability and eventually lead to P53 activation (179). However, these compounds have 
usually shown p53-independent cytotoxicity, probably by inhibiting other cellular RING 
domain E3 ubiquitin ligases (95). 
Another small molecule compound named RITA (reactivation of p53 and induction of 
tumour cell apoptosis) has been described, which binds directly to the amino terminal 
domain of P53 causing conformational changes and dissociation from MDM2 (180). This 
compound was found to have high toxicity due to its ability to cause protein-DNA crosslinks. 
However, its utility may be improved in conjunction with other selective therapies like 
MDM2 blockers (181). 
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1.7 Aims of the Study  
The hypothesis to be tested was that a careful characterisation of MDM2, MDMX and P53 
expression profiles in resected LS tumour specimens might reveal distinct relative 
expression patterns and therefore add to current, cell line-based, understanding of the 
complex interactions between these proteins in LS tissues. It was anticipated that such 
insights might also guide the selection of novel blocker compounds, of variable specificities 
and affinities, in future functional and clinical studies. 
The aim of this study was therefore to characterise the simultaneous expression levels of 
MDM2, MDMX and P53 in human LS tissues. The study examined: 
• The different patterns of MDM2 and MDMX expression.  
• The effect of their relative expression levels on the cellular levels of P53. 
• The genetic make-up (P53 mutation status) of tumours that over-expressed P53 by 
immunohistochemistry. 
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Table 1.1: Key histological and molecular features of LS subtypes 
Subtype Histological features Molecular changes 
WDLS 
Similar features to benign lipomas but 
with scattered lipoblasts and atypical 
hyperchromatic nuclei of variable sizes 
and shapes 
MDM2 amplification (nearly 100%) 
CDK4 amplification (90% ) 
DDLS 
Similar to WDLS with progression to 
components of non-lipogenic sarcoma 
of high or low grade 
MDM2 amplification (nearly 100%) 
CDK4 amplification (90% ) 
MXLS-RCLS 
Abundance of extracellular matrix 
with the presence of spindle or ovoid 
cells 
t(12;16)(q13;p11) (95%) 
t(12;22)(q13;p12) 
PLS 
Features of high grade aggressive 
sarcoma, disorderly growth patterns, 
extreme cellularity and bizarre giant 
cells 
Complex genomic imbalances 
A tabular summary of the key histological and molecular features of different subtypes of 
liposarcomas. Note the high sensitivity of the integrated molecular changes as an aiding diagnostic 
tool. WDLS = well-dedifferentiated liposarcoma; DDLS = De-differentiated liposarcoma; MXLS = 
Myxoid liposarcoma; RCLS = Round cell liposarcoma; PLS = Pleomorphic liposarcoma. 
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Figure 1.1: P53 primary structure and frequency of somatic missense mutations in 
different cancers 
This is a schematic presentation of P53 structure and its domains. The numbers are for amino 
acids. The graph shown illustrates the reported missense mutational spectrum in human cancers 
(n=19,262). Data was obtained from the P53 International Agency for Research on Cancer IARC 
website (p5 3.iarc.fr) and plotted as a function of amino acid position. Majority of mutations are 
located within the DNA-binding core domain. TAD = Transactivation domain; TD = Tetramerisation 
domain; NES = nuclear export signal; NLS = nuclear localisation signal. Adapted from WA Freed-
Pastor et al., 2013 (54). 
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Figure 1.2: MDM2 and MDMX protein structures  
This is a schematic presentation of MDM2 and MDMX protein structures showing the common 
phosphorylation sites(as indicated by P orange signs). The two proteins share structural 
similarities and are extensively phosphorylated by kinases of different classes. These include 
damage induced kinases: ATM, CHK1, CHK2, DNA-PK, ABL; and proliferation / survival kinases AKT, 
CK1, CK2, CDK1, CDK2. NES = nuclear export signal; NLS = nuclear localisation signal; NoLS = 
nucleolar localisation signal. Adapted from M Wade et al., 2010 (103) with permission from author 
(Professor G M Wahl). 
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Figure 1.3: MDM2 splice variants  
This is a schematic representation of full length MDM2 protein and its common splice variants. P1 
and P2 = promoters 1 and 2 respectively; P53 RE = P53 response elements; NES = nuclear export 
signal; NLS = nuclear localisation signal; NoLS = nucleolar localisation signal. Adapted from K 
Schuster et al., 2007 (182) with permission from publisher (American Association of Cancer 
Research). 
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Figure 1.4: MDMX-S splice variant 
This is a schematic presentation of full length MDMX and MDMX-S splice variant. MDMX-S 
consists of the P53-binding domain and 26 unique amino acids that are generated after a shift in 
the open reading frame due to the loss of exon 6. Adapted from reference F Bartel et al., 2005 (80) 
with permission from author (Dr F Bartel). 
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2 Materials and Methods 
2.1 Ethical Issues 
Ethical approval was applied for by the author. The study was reviewed and approved by the 
Leeds Central Research Ethics Committee (Reference number 10/H1313/34). The 
Committee approval permitted the use of archived STSs and other tumours held by the 
Pathology Department at LTHT. It also allowed prospective collection of fresh tissue from 
patients at the time of surgical intervention, after obtaining appropriate informed consent. 
The approval permitted the researcher to perform tissue studies and genetic analysis. This 
study complied with the Human Tissue Act. This approval was also verified by the LTHT 
Research and Development Department (Reference number MM10/9511). The ethical 
approval letter is attached in Appendix 1. 
2.2 Patient Cohorts 
Two cohorts were created for the study, a retrospective cohort of archival tissues and a 
prospective cohort of fresh samples from patients presenting to the LTHT for surgical 
intervention during the 3 year recruitment period of the study. 
2.2.1 Retrospective Cohort 
Four different sources were explored to identify liposarcoma patients who had presented to 
the LTHT since the year 2008 and the retrieved data was cross matched to avoid repetition. 
These sources included: the Sarcoma Specialist Nurse log which was kindly made available 
by Ms Emma Brown (Sarcoma Specialist Nurse, LTHT); the Electronic Hospital Records at 
LTHT via the Patient Pathway Manager (PPM) software; the LTHT Pathology Department 
electronic record; and the LTHT Cytogenetics Department Annual Audit Data, which was 
kindly provided by Dr Paul Roberts (Head of Cytogenetics Department, LTHT). The PPM 
system was able to correctly identify 90% of patients as the remaining 10% were 
inaccurately coded under other STS non-specified subtypes. 
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The relevant clinical details for the identified cohort were retrieved from the PPM system 
and occasionally from the historical medical notes, if necessary. All samples were then given 
serial numbers and anonymised accordingly. In concordance with the ethical conduct 
requirements of the study, no participant’s personal information was kept on record after 
the initial identification process. 
A total number of 64 cases were identified with a median age of 64 years. The cases were of 
a broad presentation of variants, including sex, anatomical location and histological subtype. 
The characteristics of the cohort are summarised in Table 2.1 and the full cohort is provided 
in Appendix 3.  
2.2.2 Prospective Cohort 
The Sarcoma Multi-Disciplinary Team (MDT) meetings records at LTHT were reviewed 
regularly to identify potential candidates presenting with STS or large benign lipomas, which 
required surgical resection. These candidates were first approached in the Out-Patient 
Department at the time of their surgical consultation and they were given the study 
information sheet. Candidates were then consented at their subsequent hospital admission 
for operation. The participant’s information sheet and consent form used in the study are 
attached in Appendix 2. 
A total of 16 patients were recruited prospectively in the study. These were comprised of: 
11 STS including 7 LS, 3 angiosarcomas and 1 fibroblastic tumour, with a median age of 66 
years; and 5 cases of benign tumours with a median age of 45 years. The benign tumours 
were recruited with either a known benign diagnosis or with a subsequent diagnosis based 
on histology findings supported by cytogenetic analysis. The characteristics of the 
prospective cohort are summarised in Table 2.2. 
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2.3 Materials 
2.3.1 Eukaryotic Cell Lines  
Three control cell lines were selected for analysis in this study: U2OS and SW-872 were 
obtained from the American Type Culture Collection (ATCC
®
, Manassas, USA, catalogue 
numbers. HTB-96 and HTB-92, respectively); HT29 was kindly donated by Sarah Perry 
(Senior Research Technician, Leeds Institute of Biomedical & Clinical Sciences, Wellcome 
Trust Brenner Building) and was originally obtained from ATCC
® 
(catalogue no. HTB-38). 
When the cells lines were first obtained, multiple stock vials containing the cells were frozen 
down in liquid nitrogen. Cells that were cultured beyond 25 passages from their first use 
were discarded and a new vial of frozen cells was thawed and used. 
2.3.2 Tissue Culture Reagents 
All tissue culture plastics were supplied by Corning Coaster (Buckinghamshire, UK). All 
solutions and buffers were made up in deionised filtered water, unless otherwise specified. 
The pH of all buffered solutions was adjusted to its required pH at 25˚C. 
2.3.2.1 1 x Dulbecco’s Phosphate-Buffered Saline (DPBS) (pH 7.0 – 7.2) 
500 ml stocks were obtained from Life Technologies, Carlsbad, USA (catalogue no. 14190). 
2.3.2.2 Tissue Culture Media  
Roswell Park Memorial Institute (RPMI) + GlutaMaxTM –I     
500 ml stocks were obtained from Invitrogen, Carlsbad, USA (catalogue no. 61870). 
Dulbecco's Modified Eagle’s Medium (DMEM) + GlutaMaxTM –I     
500 ml stocks were obtained from Invitrogen, Carlsbad, USA (catalogue no. 31966). 
2.3.2.3 Foetal Calf Serum (FCS) 
500 ml stock was obtained from Sigma Aldrich, St. Louis, USA (catalogue no. F7524). 
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2.3.2.4 10 x Trypsin   
100 ml stock, obtained from Life Technologies, Carlsbad, USA (catalogue no. 15400-054). 
Components of 10 x Trypsin stock are: 
Trypsin          0.5% (w/v) 
Ethylene di-amine tetra-acetic acid disodium salt (EDTA)    0.9 mM 
Sodium chloride (NaCl)        146.5 mM 
2.3.3 Cell Cycle Arrest Reagents 
2.3.3.1 Cell Cycle Arrest Drugs  
Nocodazole, Aphidicolin and Hydroxyurea were individually utilised as cell cycle arrest 
agents. They were prepared and used according to manufacturer’s instructions. Table 2.3 
summarises the conditions of use for these agents with a brief description of their 
mechanisms of action. 
2.3.3.2 Dimethyl sulfoxide (DMSO) 
500 ml stock was obtained from Sigma Aldrich, St. Louis, USA (catalogue no. D8418). 
2.3.4 Immunochemical Staining Reagents 
2.3.4.1 1 x Tris-Buffered Saline (TBS) (pH 7.4) 
Components of 1 x TBS are: 
Sodium chloride         0.15 M 
Tris-Hydrochloric acid  (Tris-HCl)       0.02 M 
1 L of 1 x TBS was made by mixing 60 ml of stock solution of 2.5 M NaCl and 20 ml 1 M Tris-
HCl (pH 7.4) in deionised water.  
2.3.4.2 Goat Serum in TBS 
The desired concentration (v/v) of goat serum in TBS was prepared by adding normal goat 
serum (Dako, Santa Clara, USA, catalogue no. X0907) to TBS. 
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2.3.4.3 Citrate Buffer 10 mM (pH 6.0) 
Components of Citrate Buffer 10mM are: 
Citric acid monohydrate (Prolabo, Radnor, USA, catalogue no. 20275.298)  10 mM 
Sodium hydroxide         26 mM 
1 L of 10 mM Citrate Buffer was prepared by dissolving the 2.10 g of citric acid monohydrate 
in deionised water, then adding 13 ml of 2 M sodium hydroxide, under constant pH 
monitoring using a calibrated pH meter (Mettler-Toledo, model no. MP220). Few drops of 2 
M sodium hydroxide may be added to achieve the desired pH before the final volume was 
set to 1 L. 
2.3.4.4 Primary Antibodies  
Four primary antibodies were used in the study, these are summarised in Table 2.4. 
2.3.4.5 Antibody Diluent  
250 ml stock was obtained from Life Technologies, Carlsbad, USA (catalogue no. 00-3118). 
2.3.4.6 Primary Antibody Detection Kit  
To detect the primary Abs, the NovoLink Max Polymer Detection System was used according 
to manufacturer’s instructions (Leica® Microsystems, Newcastle,UK, catalogue no. RE7150). 
Reagents used in the detection kit are described in the Manufacturer’s Manual. 
2.3.5 Reagents Used for Preparing Cell Lysates 
2.3.5.1 Radioimmunoprecipitation Assay (RIPA) Buffer 
100 ml stock was obtained from Thermo Scientific, Waltham, USA (catalogue no. 89900). 
Components of RIPA buffers are: 
Tris-HCl (pH 7.6)         25 mM 
Sodium chloride         150 mM 
Sodium deoxycholate         1% (w/v) 
Sodium dodecyl sulphate (SDS)       0.1% (w/v) 
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Nonyl phenoxypolyethoxylethanol (NP-40)      1% (w/v) 
2.3.5.2 Dithiothreitol (DTT)  
25 g DDT was obtained from Sigma Aldrich, St. Louis, USA (catalogue no. D0632).  
DTT 1 M stock was prepared by dissolving DTT in deionised water. It was stored at -20°C in 
small aliquots and used when needed to avoid repetitive thawing. 
2.3.5.3 Phenylmethanesulfonyl fluoride (PMSF) 
5 g PMSF was obtained from Thermo Scientific, Waltham, USA (catalogue no. 36978). 
PMSF 10 mM stock was prepared by dissolving PMSF in isopropanol. It was stored at -20°C 
in small aliquots and used when needed to avoid repetitive thawing. 
2.3.5.4 RIPA Buffer Working Solution 
Components of RIPA Buffer Working Solution are: 
RIPA Buffer          1 ml 
Protease Inhibitor Cocktail (Sigma Aldrich, St. Louis, USA, catalogue no. P8340) 1% (v/v) 
PMSF           1 mM 
DTT           1 mM 
2.3.6 Reagents Used for Protein Quantification 
2.3.6.1 Bovine Serum Albumin (BSA) Protein Standards 
(Novagen, Billerica, USA, catalogue no. 71285)     2 mg/ml 
A gradient of BSA protein standards was prepared according to manufacturer’s 
recommendations. Deionised water was used to prepare the following dilutions 0; 25; 125; 
250; 500; 750; 1000; 1500; and 2000 µg/ml. 
2.3.6.2 Bicinchoninic Acid Assay (BCA) Working Reagent Solution  
500 ml stock of BCA Solution was obtained from Novagen, Billerica, USA (catalogue no. 
71285). 
 34 
To make BCA Working Reagent Solution, the following component was added: 
4% (w/v) cupric sulphate        2% (v/v) 
2.3.7 Reagents for Western Blot 
2.3.7.1 4 x NuPage® Lithium Dodecyl Sulphate (LDS) Sample Buffer (pH 8.5) 
10 ml stock was obtained from Life Technologies, Carlsbad, USA (catalogue no. NP0007). 
Components of 4 x NuPage® LDS Sample Buffer (10 ml) are: 
Glycerol          10 % (v/v) 
Tris base (pH 8)         424 mM 
Tris-hydrochloric acid         564 mM 
LDS           2% (w/v) 
Ethylene di-amine tetra-acetic acid (EDTA)      0.5 mM 
Serva blue G250         1 mM 
Phenol red           0.7 mM 
2.3.7.2 20 x NuPAGE® MOPS SDS Running Buffer (pH 7.2) 
500 ml stock was obtained from Life Technologies, Carlsbad, USA (catalogue no. NP0001) 
Components of 20 x NuPAGE® MOPS SDS Running Buffer (500 ml) are: 
3-(N-morpholino) propane sulphuric acid (MOPS)      1.0 M 
Tris base (pH 8)         1.0 M 
Sodium Dodecyl Sulphate (SDS)       70 mM 
EDTA (pH 8)          20 mM 
2.3.7.3 20 x NuPAGE® MOPS SDS Transfer Buffer (pH 7.2) 
500 ml stock was obtained from Life Technologies, Carlsbad, USA (catalogue no. NP0006) 
Components of 20 x NuPAGE® MOPS SDS Transfer Buffer (500 ml) are: 
Bicine           500 mM 
Bis-Tris          500 mM 
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EDTA (pH 8)          20 mM 
2.3.7.4 β-Mercaptoethanol  
(Sigma Aldrich, St. Louis, USA, catalogue no. M3148)    14.3 M 
2.3.7.5 Precast NuPAGE® Novex® 4-12% Bis-Tris Gel (0.1 mm, 10 wells) 
(Invitrogen, Carlsbad, USA, catalogue no. cat no. NP0321) 
2.3.7.6 Protein Molecular Weight Markers  
A- Magic Mark
TM
 XP (range: 20 - 220 kDa) 
50 µl stock was obtained from Life Technologies, Carlsbad, USA (catalogue no. LC5603) 
B- Precision Plus Protein Standards – Dual colour (range: 10 – 250 kDa) 
500 µl stock was obtained from Bio-Rad, Hercules, California (catalogue no. 161-0374) 
C- Pre-stained Protein Marker (range: 6 – 175 kDa) 
500 µl stock was obtained from BioLabs Inc., Ipswich, USA (catalogue no. P7708) 
2.3.7.7 Amersham Hybond-P Polyvinylidene difluoride (PVDF) membrane 
(GE Healthcare, Little Chalfont, UK, catalogue no. RPN2020F) 
2.3.7.8 Tween-20  
100 ml stock was obtained from Fisher Scientific, Waltham, USA (catalogue no. BP337-100) 
2.3.7.9 TBS Tween (TBST) 
TBS (pH 7.4) as described in Section 2.3.4.1 
Tween -20           0.1 % (v/v) 
2.3.7.10 Secondary Antibodies Used in Western Blot 
A- Polyclonal rabbit anti mouse horseradish peroxidase (HRP) conjugated  
5 ml stock was obtained from Dako, Santa Clara, USA (catalogue no. P0260) 
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B- Polyclonal swine anti rabbit HRP conjugated 
5 ml stock was obtained from Dako, Santa Clara, USA (catalogue no. P0217) 
2.3.7.11 SuperSignal® West Femto Chemiluminescent Substrate  
100 ml stock was obtained from Thermo Scientific, Waltham, USA (catalogue no. 34095) 
2.3.8 Reagents Used for DNA Extraction  
A- DNA extraction from FFPE tissue blocks  
2.3.8.1 QI Amp
® 
DNA FFPE Tissue Kit 
(Qiagen, Venlo, Netherlands, catalogue no. 56404)     50 tests 
B- DNA extraction from tissue culture  
2.3.8.2 QI Amp
® 
DNA Mini Kit  
(Qiagen, Venlo, Netherlands, catalogue no. 51304)     50 tests 
2.3.8.3 Agarose Gels (variable concentrations)  
Agarose (Severn Biotech Ltd, Kidderminster, UK, catalogue no. 30-17-50)  % (w/v) 
1 x Tris-Acetate EDTA (TAE) (pH 8) (volume as required)    ml 
(Severn Biotech Ltd, Kidderminster, UK, catalogue no. 20-6001-50) 
Ethidium bromide (10mg/ml)        2µg/100ml 
(Promega, Madison, USA, catalogue no. H5041) 
2.3.8.4 Gel Electrophoresis 6 x loading dye  
1 ml stock was obtained from Promega, Madison, USA (catalogue no. G1881) 
2.3.8.5 Genomic Molecular Weight Markers 
A- GeneRuler
TM 
100 bp DNA Ladder (range: 100 – 1000 bp) 
1 ml stock was obtained from Fermentas, Waltham, USA (catalogue no. SM0241) 
B- Lambda DNA / Hind III Marker (range: 125 – 23130 bp) 
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1 ml stock was obtained from Fermentas, Waltham, USA (catalogue no. SM0103) 
2.3.9 Reagents Used For Polymerase Chain Reaction 
2.3.9.1 5 X Go Taq flexi PCR buffer (pH 8.5) 
20 ml stock was obtained from Promega, Madison, USA (catalogue no. M890) 
2.3.9.2 Magnesium Chloride (MgCl2) Solution (25 mM) 
1.5 ml stock was obtained from Promega, Madison, USA (catalogue no. A5311) 
2.3.9.3 Primers 
The P53, MDM2 and MDMX primers used in the study are summarised in Table 2.5. 
Stocks of 10 micromolar (µM) of each primer were stored at -20˚C. 
2.3.9.4 Deoxynucleoside Triphosphates (dNTP) 
10 mM stock of dNTP was prepared from the following and stored at -20˚C: 
100 mM deoxyadenosine triphosphate (dATP) 
(Fisher Scientific, Waltham, USA, catalogue no. BP2564-1A)   100 µl 
100 mM deoxycytidine triphosphate (dCTP) 
(Fisher Scientific, Waltham, USA, catalogue no. BP2564-1B)   100 µl 
100 mM deoxyguanosine triphosphate (dGTP)  
(Fisher Scientific, Waltham, USA, catalogue no. BP2564-1C)   100 µl 
100 mM deoxythymidine triphosphate (dTTP) 
(Fisher Scientific, Waltham, USA, catalogue no. BP2564-1D)   100 µl 
2.3.9.5 GenElute PCR Clean up Kit  
(Sigma Aldrich, St. Louis, USA, catalogue no. NA1020)    100 tests 
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2.3.10 Reagents for Big Dye Sanger Sequencing 
2.3.10.1 BigDye® Terminator v3.1 Cycle Sequencing Kit  
(Applied Biosystems Inc., Warrington, UK, Catalogue no. 4337455) 
Components of kit are: 
Big Dye 3.1          800 µl 
5 x Sequencing Buffer         4 ml 
2.3.10.2 Ethylene di-amine tetra-acetic acid (EDTA) 
500 g stock was obtained from Duchefa, Haarlem, Netherlands (catalogue no. E0511) 
2.3.10.3 Highly Deionised (HiDi) Formamide  
25 ml stock was obtained from Life Technologies, Carlsbad, USA (catalogue no. 4311320) 
 
2.4 Methods 
2.4.1 Tissue Samples Processing and Storage  
2.4.1.1 Retrospective Samples  
Archival tissue blocks were collected from the Pathology Department at LTHT after the 
appropriate approvals were granted. In accordance with the Human Tissue Authority (HTA) 
regulations and the ethical permissions for the study, the samples were afterwards stored in 
a secure, HTA-registered tissue storage facility (room 9.04f, Wellcome Trust Brenner 
Building).  
2.4.1.2 Prospective Samples 
Fresh tissue samples were delivered immediately to the Pathology Department at LTHT after 
surgical resection, in a fresh preservative-free state. The specimen was marked and cut by a 
consultant histopathologist with the researcher attending. A fresh sample was collected for 
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the purpose of the study. It was immediately cut into small cubes of tissue (approximately 1 
cm
3
 in size) and the cubes were stored in pre-labelled cryo-tube vials (Thermo Scientific, 
Waltham, USA, catalogue no. 366656). They were immediately immersed in liquid nitrogen 
for 2 minutes, before being frozen at -80°C. An updated log of all archival and fresh 
specimens prepared for the study was maintained and kept securely. 
2.5 Propagation of Eukaryotic Cell Lines 
The materials used in these experiments are detailed in Section 2.3.2. 
U2OS and HT29 were routinely maintained in RPMI + GlutaMaxTM –I with 10% (v/v) FCS and 
SW-872 was maintained in DMEM + GlutaMaxTM –I with 10% (v/v) FCS. They were 
incubated in a humidified incubator with 5% CO2 at 37°C and the media were changed every 
three days. The cells were passaged once they reached 90 – 95% confluence. No antibiotic 
or antifungal reagents were used. For passage, cells were rinsed in DPBS for 1 minute, 
before incubation in 1 x trypsin solution in DPBS for 10 minutes. Single cell suspensions 
were passaged at a ratio of 1:10. 
2.6 Cell Cycle Arrest Protocol 
The materials used in these experiments are detailed in Section 2.3.2. 
Cells were grown on 22 x 22 mm, 0.13 – 0.16 mm thick cover slips (VWR International, 
Leicestershire, UK) in 6-well tissue culture plates, in aseptic controlled conditions. They were 
then incubated at 37°C in 5% CO2 until they had reached the desired confluence 
(approximately 40%). Their cell cycle was arrested across different phases using one of three 
cell cycle arrest agents (Nocodazole, Aphidicolin and Hydroxyurea). To establish the 
optimum doses, increasing concentrations of each of these agents, in the relevant tissue 
culture media, were used until the lethal doses were identified. The tissue cultures were 
then incubated with each of the cytotoxic agents at the highest, non-lethal dose (Table 2.3) 
for 24—48 hours (hrs). Control samples were incubated in 1 mM DMSO at similar (v/v) 
concentrations to each of the cell cycle arrest agents. The cells were inspected under 
inverted light microscope (Olympus, model no. CKX41). They were used after visual 
confirmation of their viability and unanimous morphology. Subsequently, slides were fixed 
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in neat methanol (-20˚C) for 10 minutes, then washed and maintained in DPBS. Fixed slides 
were kept in the fridge (4˚C) afterwards and ICC was performed within 24 hrs of fixation. 
2.7 Immunochemical Staining Protocol 
The materials used in these experiments are detailed in Section 2.3.3. 
2.7.1 Immunocytochemistry (ICC) 
To perform ICC, cells were grown on 22 x 22 mm cover slips (until 40% confluent), fixed in 
methanol and then washed and maintained in DPBS, as described in Section 2.6. ICC was 
performed within 24 (hrs) of fixation. No antigen retrieval procedures were required. 
After the slides were washed in TBS, endogenous peroxidase was neutralised by 3% (v/v) 
hydrogen peroxide in water for 20 minutes, followed by protein block with 3% (v/v) casein 
in DBPS (as provided in the NovoLink Max Polymer Detection System) for 10 minutes to 
reduce non-specific primary antibody (Ab) binding. Subsequently, the slides were incubated 
with the optimally diluted primary Abs in Invitrogen® Antibody Diluent as follows: P53, 
1:100 for 12 hrs at 5°C; MDM2 (SMP-14), 1:300; and MDMX, 1:200, both for 1 1hr 
incubation time. The primary Abs used in the study are summarised in Table 2.4. 
2.7.1.1 Detection of the Primary Antibody 
To detect the primary Abs the NovoLink Max Polymer Detection System was used. The 
system employs a controlled polymerisation to prepare polymeric Horseradish Peroxidase 
(HRP)-linker antibody conjugates. After TBS wash of the primary Ab, slides were incubated 
for 30 minutes in a serum-based post-primary block to enhance penetration of the polymer 
reagents. They were then incubated for another 30 minutes in the HRP polymer-conjugated 
secondary Ab, which had positive reactivity to mouse IgM, mouse IgG and rabbit IgG. 
Subsequently, the slides were incubated for 5 minutes in 3,3’- diaminobenzidine (DAB) 
chromogen, which produces a visible brown precipitate at the antigen site when oxidised by 
HRP of the secondary Ab. All the previous steps were separated by 5-minute washes in TBS, 
repeated twice. The counterstaining was performed with 0.02 % (v/v) haematoxylin in 
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water, for 2 minutes. After a brief wash in tap water, coverslips were then mounted on 
slides, which were visualised under a light microscope (Nikon, model no. Eclipse E600). 
2.7.2 Immunohistochemistry (IHC) 
Formalin-fixed and paraffin-embedded (FFPE) tissue blocks were cut at 4 µm thickness with 
a microtome (Leica, model no. RM 2255), to obtain sequential sections. Sections were 
floated in a water bath at 39 – 42 °C before transfer onto Superfrost Plus slides (Thermo 
Scientific, Waltham, USA, catalogue no. 4951PLUS4). They were incubated overnight at 
37°C. Slides were de-waxed by serial immersion in a xylene-to-ethanol (3 x 100% xylene 
washes followed by 3 x 96% ethanol washes). Antigen retrieval was performed by 
immersing the slides in a hot bath of 1mM citrate buffer (pH 6.0) at 95 -98°C for 20 minutes. 
After cooling for 20 minutes at room temperature, the slides were washed for 5 minutes in 
deionised water and a further 5 minutes in TBS. Endogenous peroxidase was blocked by 3% 
(v/v) hydrogen peroxide in water for 20 minutes, then non-specific primary Ab binding was 
blocked with 20% (v/v) goat serum in TBS for 30 minutes. The slides were incubated with 
primary Abs diluted in 5% (v/v) goat serum in TBS at the concentrations found after 
optimisation, which were within the ranges recommended by the manufacturers, as follows: 
for MDM2 (SMP-14) at a dilution of 1:250 for 90 minutes; for MDMX at 1:250 dilution; and 
for P53 at a 1:600 dilution. Both of the latter were incubated for 18 hours at 5°C. All 
previous steps were separated by 5-minute washes in TBS, repeated twice. 
To detect the primary Abs, the NovLink Max Polymer Detection System was used, as 
detailed in Section 2.7.1.1. The slides were counter-stained with haematoxylin, dehydrated 
through an ethanol-to-xylene solvent gradient and mounted under glass cover slips. 
2.7.2.1 Optimisation of Immunochemical Protein Detection 
Conditions for use of the antibodies in ICC and IHC with cell lines and LS cancer tissue were 
optimised by series of experiments, which included adjusting the following parameters: 
A- Optimisation of Antigen Retrieval Techniques  
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Multiple antigen heat retrieval techniques, using 1 mM citrate buffer solution (pH 6.0) were 
employed. These included: microwave oven heat application at 800 watt for 10 minutes; 
pressure cooker retrieval for 2 minutes and immersing the slides in sub-boiling citrate buffer 
bath (95-98 °C) for 5 - 30 minutes. 
B- Optimisation of the Blocking Compounds 
To block the non-specific Ab binding, two blocking compounds were used either separately 
or in conjunction with one another. These included: 0.4% casein in phosphate-buffered 
saline (as provided in the NovoLink Max Polymer Detection System), for an incubation 
period of 5 - 10 minutes and 20% (v/v) goat serum in TBS for 10 minutes. 
C- Optimisation of the Primary Antibodies 
Decreasing primary Ab concentrations were used until a negative signal was obtained, to 
achieve optimal dilution results. Variable incubation periods from 1 hr to overnight were 
performed until the most specific results were achieved. Different antibody diluents were 
used including Invitrogen Antibody Diluent and 5% (v/v) goat serum in TBS. 
2.7.2.2 Routinely Used Immunochemical Staining Controls 
No primary and no secondary Ab controls were included in each ICC and IHC run. At least 
one positive and one negative tissue controls were analysed with each IHC run. 
The negative controls for P53, MDM2 and MDMX included: normal fat from breast tissue 
kindly provided by Professor Valerie Speirs (Professor of Experimental Pathology and 
Oncology, University of Leeds) and a fully characterised, subcutaneous benign lipoma. 
P53 positive control was a metastatic adenocarcinoma in a lymph node. MDDM2 and 
MDMX positive controls included two fully characterised LSs with known MDM2 or MDMX 
amplification, respectively. All control samples were tested and validated for use by the 
Pathology Department at LTHT. They were kindly provided and proof read by Dr Will 
Merchant (Consultant Histopathologist, LTHT). 
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2.7.2.3 Immunohistochemistry Scoring Protocol 
Scoring for the IHC stained tissue slides was performed on a light microscope (Olympus 
multi-viewer, model no. BX41) at 40 x magnification. This was done simultaneously but 
independently by the author and an experienced histopathologist. Both were blinded to the 
actual histological diagnosis. 100 cells per slide were scored (maximum of 20 cells per high 
power field). Particular care was taken to mark the sequential slides of each case identically, 
so as to score corresponding fields for the three different antibodies. 
Only clear nuclear staining was considered positive. Blood cells, inflammatory cells, non-
specific cells and capillary endothelium cells were not included in the scoring process. 
Mitotic figures were excluded (as will be explained in Section 3.2.3). Scoring was stratified 
for MDM2 and MDMX as (-, + and ++) where <11, 11-40 and >40 of the 100 cells were 
stained positive, respectively. P53 was considered over-expressed (+) if 10% or more cells 
had positive nuclear staining. The slides were then proof read and re-scored separately by a 
specialist consultant histopathologist. 
2.7.2.4 Data Analysis 
Basic statistical tests were performed in the study. Statistical analysis was done using SPSS 
software - version 21, (SPSS Inc., Illinoi, USA). P values <0.05 were considered significant.  
The project statistics were reviewed and approved by Dr Helene Thygesen, biostatistician 
(Cancer Research UK, Leeds Centre). 
2.8 Immune Blotting of Proteins  
2.8.1 Cell Lysate Preparation and Quantification  
The materials used in these experiments are detailed in Sections 2.3.5 and 2.3.6. 
2.8.1.1 Preparation of Lysate from Cultured Cells 
Western blots for a protein of interest were performed using lysates prepared with 
Radioimmunoprecipitation Assay (RIPA) buffer. Cells were grown in T75 flasks until 40 – 50% 
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confluent, media were removed and cells were washed in their relevant, cold and FCS-free 
media. To counteract endogenous enzymes, Protease Inhibitor Cocktail; PMSF; and reducing 
agent (DTT) were added to make the RIPA Buffer Working Solution (see Section 2.3.5.4). The 
cells were incubated with 1 ml of the RIPA Buffer Working Solution and allowed to stand for 
10 minutes at 4°C before dislodging the cells with a tissue scraper and transferring the 
solution to a 1.5 ml microfuge tube (Eppendorf). The solution was pipetted up and down to 
break up any clumps, and then incubated on ice for another 10 minutes. Subsequently, the 
solution was centrifuged for 10 minutes at 16,000 g at 4°C. The supernatant lysate was 
quantified for protein concentration (as per Section 2.8.1.3) and stored at -80°C. 
2.8.1.2 Preparation of Lysate from Frozen Tissue 
Frozen tissue sections were mounted on a chuck using mounting medium (VWR, Leuven, 
Belgium, cat no. 361603E) before being cut with a cryostat (Leica, model no. CM3050 S) at 5 
µm thickness. The first two sections were discarded and the subsequent four sections were 
transferred into 1.5ml Eppendorfs containing 500 µl of RIPA Buffer Working Solution. The 
samples were then processed and stored as described in Section 2.8.1.1. 
2.8.1.3 Quantification of Proteins  
The protein concentration of the lysates was quantified using a Bicinchoninic Acid Assay 
(BCA) protein assay kit. This analysis is based on a colourimetric assay of a Biuret reaction, 
which utilises the reduction of Cu
+3
 to Cu
+2
 by proteins in an alkaline solution, in a 
concentration-dependent reaction leading to a measurable violet colour. 10 µl of either the 
cell lysate, RIPA buffer standard, or serial dilutions of the BSA protein standard (see Section 
2.3.6.1) with 15 µl of deionised water were added to each well of a 96-well microtitre plate, 
then 200 µl of BCA Working Reagent Solution containing cupric sulphate (see Section 
2.3.6.2) was added to each well and mixed thoroughly before incubation at 37°C for 30 
minutes. Optical density was subsequently measured using a microplate reader (Dynex 
Technologies Ltd, model no. Opsys MRTM) at 570 nm. The protein concentration of the 
lysate samples were first corrected for the RIPA buffer standard measurement, then 
calculated from the standard curve obtained from the serial dilutions of the BSA protein 
standards. 
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2.8.2 Western Blot  
The materials used in these experiments are detailed in Section 2.3.7. 
2.8.2.1 Gel Electrophoresis of Proteins 
A mass equivalent of 20 µg of protein was added to 1 x LDS sample buffer (pH 8.5) 
containing 5% (v/v) β-mercaptoethanol, to make up a total volume of 20 μl. Samples were 
briefly mixed, spun and placed in a hotplate at 100°C for 5 minutes before being transferred 
into ice for 5 minutes. Afterwards, samples were centrifuged for 30 seconds, gently 
suspended and kept on ice, before being loaded onto the gel. 
Twenty μg of samples was loaded onto Precast NuPAGE® Novex® 4-12% Bis-Tris Gel with 5 
μl molecular weight markers in adjacent lanes (either Precision Plus Protein Standards or 
Prestained Protein Marker were used). 5 μl of Magic Mark
TM
 XP was added to each ladder to 
allow band visualisation on the running gel. Electrophoresis was then performed in Xcell 
SureLock™ Mini-Cell system (Life Technologies, model no. EI0001), in 1 x NuPAGE® MOPS 
SDS Running Buffer, at a constant current of 180 V for 1 to 1.5 hrs. 
2.8.2.2 Transblotting of Bis-Tris Gels 
Proteins that were separated using the gel electrophoresis were then transferred onto 
Amersham Hybond-P Polyvinylidene difluoride (PVDF) membrane. The membrane was 
activated by being soaked in neat methanol for 30 sec then washed in deionised water for 
10 minutes with constant agitation on a shaker. Proteins were then transferred in 1 x 
NuPAGE® MOPS SDS transfer buffer with 10% (v/v) methanol, using the XCell II Blot Module 
(Life Technologies, Carlsbad, USA, catalogue no. EI9051) for 16 hrs at 12 V. 
2.8.2.3 Immunoblotting of Proteins 
The PVDF membrane with the transferred protein was blocked with TBS containing 0.1% 
(v/v) Tween-20 (TBST) and 5% (w/v) skimmed dried milk (Marvel) for 1 hour at room 
temperature with gentle agitation. It was then transferred to 1% (w/v) skimmed dried milk 
(Marvel) in TBST containing the primary Ab in appropriate dilutions as follows: 1:5000 for 
P53 (DO-7) and MDMX; 1:2500 for MDM2 (SMP-14); and 1:4000 for MDM2 (2A10). The 
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membrane was allowed to incubate with the primary Ab for 90 minutes at 37°C, it was then 
washed, thrice, with TBST, for ten minutes each time. 
The membrane was then transferred to 1% (w/v) dried skimmed milk (Marvel) in TBST 
containing the appropriate secondary Abs in 1:2000 dilution as follows: for P53 and MDM2, 
polyclonal rabbit anti mouse HRP conjugated; and for MDMX, polyclonal swine anti rabbit 
HRP conjugated. The membrane was incubated with the secondary Ab for one hour at room 
temperature, then washed, trice, TBST for 15 minutes. To rule out non-specificity of 
secondary Ab, samples incubated without primary Ab were included in the early stages of 
the investigation. 
To detect the bound Abs, the membrane was incubated with 200 µl of SuperSignal® West 
Femto Chemiluminescent Substrate for 5 minutes, before being visualised using ChemiDoc® 
MP imaging system (Bio-Rad, model no. 170-8280), with exposure time periods of 1 minute 
to 1 hr depending on the level of signal intensity. 
2.9 Cytogenetic Analyses  
Cytogenetic analyses were performed by the Yorkshire Regional Genetics Services (Ashley 
Wing, St James’s University Hospital) as part of the diagnostic protocols of LSs. This service 
was introduced in 2008 and has subsequently become a routine diagnostic tool. Two 
separate tests were performed for LSs including Giemsa banding for karyotype analysis as a 
“road map” for subsequent Fluorescence in situ hybridization (FISH) analysis to detect 
MDM2 amplification. 
2.9.1.1 Fluorescence in situ Hybridization 
The methods adopted by the Yorkshire Regional Genetics Services to perform FISH analysis 
can be summarised as follows. FISH analysis was performed on FFPE tissue slides, guided by 
a complementary haematoxylin and eosin pre-stained slide provided by histopathologist 
and marked for the areas of tumour cells. Briefly, the slides were de-waxed and dehydrated 
in a gradient of xylene and ethanol. They were then incubated in 0.2M HCl for 30 minutes to 
compromise the integrity of the nuclear membranes, before being washed with distilled 
water. Slides were pre-treated by pepsin and incubated in a hybrite for 45 minutes. 
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Hybridisation was achieved by adding 5 µl of DNA probe which hybridises to the MDM2 
locus at 12q15 with a 12 centromere control (Keratech, Amsterdam, Netherlands, catalogue 
no. KBI-10717 MDM2(12q15)/SE12) and the slides were kept on a hot plate (80˚C) for 5 
minutes to denature the DNA for probe attachments, they were then incubated at 37˚C 
overnight. Finally, more washes and 4',6-diamidino-2-phenylindole (DAPI) counterstaining 
were performed before the slides were ready for analysis. 
2.9.1.2 Fluorescence in situ Hybridization Scoring Protocol 
A total of 100 cells were scored independently by two trained technicians using fluorescent 
microscopes (Leica DMLB; Leica DMR; and Zeiss Axioplan 2) and the scorers were blinded to 
the provisional histological diagnosis. Only cells with clear cell boundaries were scored. 
Overlapping nuclei were also excluded. A fourfold increase in MDM2 (red) signal, compared 
to centromere (green) signal, was considered positive for MDM2 amplification. At least 5 of 
the scored 100 cells had to demonstrate these changes to conclude the case was positive for 
MDM2 gene amplification. Other characteristic features of gene amplification that were 
occasionally seen included the presence of supernumerary rings or a giant chromosome in 
karyotype analysis.  
2.10 Genetic Analysis  
2.10.1 Extraction of Deoxyribonucleic Acid (DNA) 
The materials used in these experiments are detailed in Section 2.3.8. 
2.10.1.1 DNA Extraction from Formalin-Fixed Paraffin-Embedded Blocks 
QI Amp
® 
DNA FFPE Tissue Kit was used to extract genomic material from FFPE tissue blocks 
for subsequent analysis. The kit utilises the selective binding properties of a silica-based 
membrane to purify DNA from small samples, and the manufacturer’s instructions were 
followed accurately. The tissue blocks were first cut using a microtome at 5 µm thickness, 
the first two sections were discarded and the subsequent 3 – 5 sections (no more than 25 
mg) were kept in 1.5 ml Eppendorf tubes. De-waxing and rehydration were done by adding 
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1.2 ml of xylene with rigorous vortexing followed by centrifugation at 13,000 g for 2 
minutes. The supernatant was removed and the pellet was resuspended in 1.2 ml of 100% 
ethanol to remove any residual xylene. Gentle vortex was then followed by centrifugation at 
13,000 g for 2 minutes, the supernatant was removed and the obtained pellet was allowed 
to air dry at room temperature for 10 minutes. The tissue pellet was then re-suspended in 
180 µl of ATL buffer with 20 µl proteinase K (20mg/ml) and was incubated for 1 hr at 56°C to 
ensure adequate sample lyses. This was followed by 1 hour incubation at 90°C to reverse 
formalin crosslinking, and the sample was then dissolved in 200 µl of Buffer AL with 200 µl 
of 100% ethanol, before being transferred to QI Amp spin column and centrifuged at 6000 
g for 1 minute. The filtrate was discarded as DNA was bound to the silica membrane in the 
column. The residual contaminants were washed with 500 µl of Buffers AW1 and AW2 
consecutively, separated by 6000 g centrifuge for 1 minute each. DNA was subsequently 
eluted into a clean 1.5 ml Eppendorf in 40 µl of nuclease-free water (or ATE Buffer). The 
eluate containing DNA was stored at -20˚C until further use. Nucleic acid concentration 
was measured using a NanoDrop
TM
 1000 Spectrophotometer (Thermo Scientific, Waltham, 
USA). 
2.10.1.2 DNA Extraction from Cultured Cells  
QI Amp
® 
DNA Mini Kit was used to extract genomic material from cultured cell lines. The kit 
utilises a silica membrane column as described in Section 2.7.6.1. Cells were grown in T75 
Corning tissue culture flasks in their appropriate media. When they reached 50% 
confluence, media was removed and cells were washed in DPBS then incubated with 1 x 
trypsin for 10 minutes at 37˚C, until they had detached from the flask. They were then 
resuspended in 10 ml of their culture media into a collection tube. The cell suspension was 
centrifuged at 300 g for 10 minutes and the media supernatant was discarded. The pellet 
was resuspended in DPBS to a final volume of 200 µl before 20 µl proteinase K (20mg/ml) 
and 200 µl of Buffer AL were added separately. The solution was incubated at 56°C for 10 
minutes and then 200 µl of 100% ethanol was added with gentle vortex. The solution was 
transferred to QIAamp Mini spin column and centrifuged at 6000 g for 1 minute, the filtrate 
was discarded and the DNA was bound to the silica membrane in the column. Subsequently 
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the contaminants were washed off in Buffers AW1 and AW2 and DNA was eluted and stored 
as described in Section 2.7.6.1. 
2.10.1.3 Agarose Gel Confirmation of DNA Extraction 
1 % (w/v) agarose gel was prepared by adding the required weight of agarose to a volume of 
1 x TAE, the solution was warmed in a microwave oven until agarose had dissolved, then 
cooled to 50
0
C, an equivalent of 2 µg/100ml ethidium bromide was added and mixed well. 
The gel was then poured into an appropriate sized rig with a comb in place. Once cooled, 
the comb was removed to reveal the wells. 
4 µl of each DNA eluate with 3 µl of 6 x agarose gel loading dye was loaded into the 
ethidium bromide- stained agarose gel, and an appropriate genomic molecular weight 
ladder was loaded into adjacent lane. Horizontal gel electrophoresis was performed in a gel 
casting system (Life Technologies, model no. Horizon® 58 or Bio-Rad, model no. Sub-Cell® 
GT) in 1 x TAE buffer, at a constant current of 60 V (5V per cm of distance between 
electrodes) for 40 minutes. The gel was then visualised under ultra-violet (UV) light at 306 
nm, via the fluorescence of intercalated ethidium bromide, using the ChemiDoc® MP 
imaging system (Bio-Rad, model no. 170-8280). 
2.10.2 The Polymerase Chain Reaction 
The materials used in these experiments are detailed in Section 2.3.9. 
2.10.2.1 Oligonucleotide Primer Design  
Oligonucleotide primers for Polymerase Chain Reaction (PCR) amplification and sequencing 
of MDM2 and MDMX sequences were designed against the human genome (Genome 
Reference Consortium Human Build 37) as annotated by University of California, Santa Cruz 
(UCSC) genome browser (183). Primers were designed to flank each coding exon, the donor 
and acceptor splice sites and about 100 bp of flanking intronic DNA. The oligonucleotide 
primer sequences for amplification and sequencing of P53 coding sequences were 
reproduced from reference (184). 
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2.10.2.2 The Polymerase Chain Reaction Protocol 
Stocks of 10 µM primers and 20 ng/µl DNA extracts were prepared by dilution in sterile 
water. All PCRs were initially performed on a thermal gradient (45°C – 65°C) using Peltier 
Thermal Cycler (Bio-Rad, model no. PTC0220), to determine the optimal annealing 
temperature for each primer pair reaction. This standard protocol was sufficient to identify 
the optimal annealing temperatures for all different primers (Table 2.5). 
PCRs were performed in 25 µl total reaction volumes containing: 1 x Go Taq flexi PCR 
reaction buffer, 1.5 mM MgCl2, 200 µM of each (dNTP) [ (dATP); (dGTP); (dCTP); (dTTP)], 200 
nanomolar (nM) of each primer, 1.5 units of Taq DNA polymerase and template genomic 
DNA (approximately 50 ng). Double-stranded DNA was denatured by heating to 95°C for 3 
minutes, followed by 40 cycles of the following steps: denaturing at 95°C for 30 seconds; 
cooling to 50-59°C for 30 seconds to allow the primers to anneal to their complementary 
sequences; heating to 72°C for 30 seconds to extend the annealed primers with Taq DNA 
polymerase. The final cycle was complemented by an extension of 72°C for 2 minutes. A 
negative control of all reagents excluding genomic DNA was included in all experiments, as 
was a positive control of previously analysed DNA (from human blood), which was kindly 
made available by Dr Christine Diggle (Senior Research Fellow, Wellcome Trust Brenner 
Building). 
2.10.2.3 Standard Agarose Gel Electrophoresis 
At the conclusion of each PCR, standard 1% (w/v) agarose gel electrophoresis was 
performed to confirm a successful reaction was achieved by the detection of a 
transluminant band, which corresponded with the expected PCR amplicon size against 100 
bp DNA ladder. 4 µl of PCR products was added to 3 µl of 6 x agarose gel loading dye and 
horizontal agarose gel electrophoresis was performed according to the protocol detailed in 
Section 2.7.6.3. 
2.10.2.4 Purification of PCR Products 
The PCR products were purified of unincorporated oligonucleotide primers using GenElute 
PCR clean up kit. The kit is designed for purification of single-stranded or double-stranded 
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PCR amplification products of a size range between 100 bp to and 10 kb. The purification 
was achieved by first activating the silica membrane of the GenElute plasmid mini spin 
column with 0.5 ml of Column Preparation Solution to maximise the DNA binding. The 
column was centrifuged at 16,000 g for 1 minute, and the eluate was discarded. Then, the 
PCR products were diluted in 5 x (v/v) Binding Solution and passed though the silica 
membrane (by centrifugation at 16,000 g for 1 minute) to allow DNA binding to the 
membrane. The eluate was discarded. The bound DNA was then washed and cleaned by 0.5 
ml of Wash Solution, centrifuged at 16,000 g for 1 minute, twice and the eluate was 
discarded. Finally the PCR products were eluted in 25 µl nuclease-free water into a clean 
Eppendorf and stored at -20˚C until further use.  
The purified products were quantified for nucleic acid concentrations using Nanodrop and 
standard agarose gel electrophoresis was performed, as per protocol detailed in Section 
2.7.6.3, for confirmation of retained purified PCR products. 
2.10.3 DNA Amplicon Dye Terminator Cycle Sequencing 
DNA analysis of MDM2 and MDMX was performed in the control cell lines and of P53 in 
selected FFPE tissue blocks. The materials used in these experiments are detailed in Section 
2.3.10. 
The DNA sequencing was performed using BigDye® Terminator v3.1 Cycle Sequencing Kit, 
according to the manufacturer’s instructions. DNA sequencing of P53 exon 4 to 9; MDM2 
exon 1 to 11; MDMX exon 1 to 10 and flanking intervening sequences was performed using 
PCR fragments covering these regions. Sequencing was performed on purified PCP 
amplicons (as described in Section 2.7.7.4) using the same oligonucleotide primers that 
were used for exon amplification. The sequences were aligned to reference sequences: 
NT_010718.16 for P53; NT_029419.12 for MDM2; and NT_00487.19 for MDMX. Sequencing 
was obtained from both forward and reverse strands. 
2.10.3.1 Sequencing Reaction  
Sequencing reactions were performed in a 96-well plate and consisted of the following: 1 µl 
of the template PCR product; 1 µl BigDye
TM
 3.1 Terminator ready Reaction Mix; 1.5 µl 5 x 
 52 
Sequencing Buffer, 1.6 picomolar (pM) of the forward or reverse corresponding primer, 
sterile water to make up the solution to a final volume of 10 µl. The reagents were pipetted 
and mixed well. Cycle sequencing was performed with rapid thermal ramping on a Peltier 
Thermal Cycler (Bio-Rad, model no. PTC0220), using 25 cycles of the following steps: 96°C 
for 10 seconds; 50°C for 5 seconds and 60°C for 4 minutes. Each change in temperature was 
performed by ramping the temperature up or down at the rate of 1 °C per second.  
2.10.3.2 Ethanol Precipitation to Remove Unincorporated Dyes 
DNA material and its extension products were precipitated by adding 5 µl of 125 mM EDTA 
(pH 8.0) and 60 µl of 100% ethanol to each 10 µl reaction solution. The mixture was 
thoroughly mixed and centrifuged at 3060 g for 30 minutes at room temperature, the plate 
was then inverted on a clean tissue and re-centrifuged at 8 g for 1 minute.  
The resulting pellet was then washed with 60 µl of freshly-prepared 70% ethanol and 
immediately centrifuged at 780 g for 15 minutes at 4°C to remove EDTA and the 
unincorporated dye-terminators. The plate was then inverted and centrifuged at 8 g for an 
additional minute before it was left to air-dry. Each ethanol-precipitated products pellet was 
re-suspended in 10 µl highly deionised (HiDi) formamide and the sequencing reactions were 
visualised by electrophoresis on a Genetic Analyser (Applied Biosystems, model no. 3130xL). 
2.10.3.3 Sequence Analysis 
Data from the 3130xL Genetic Analyser were exported as (.ab1) files and analysed using 
GeneScreen, a program developed by Dr Ian Carr (Lecturer, University of Leeds), for high-
throughput mutation detection in DNA sequence electropherograms (185) 
(http://dna.leeds.ac.uk/genescreen). Identification, verification and annotation of sequence 
variants were performed using this software. 
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Table 2.1: Characteristics of the retrospective patients cohort 
Category Subcategory Result (n) 
Sex Female 33 (median age = 63) 
 Male 31 (median age = 64) 
Anatomical location  Trunk 29 (15 retroperitoneal) 
 Extremities  35 
Histological subtype WDLS 43 (including 1 inflammatory 
and 1 mixed type)   
 DDLS 9 
 MXLS-RCLS 12 
This is a tabular summary of the characteristics of the retrospective clinical cohort demonstrating 
a homogenous distribution amongst gender, age and tumour subtypes and anatomical locations. 
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Table 2.2: Characteristics of the prospective patients cohort 
Category Subcategory Results (n) 
Sex Female 12 (median age = 58.5) 
 Male  4 (median age = 57.5) 
Anatomical location Trunk 6 
 Retroperitoneum  10 
Histology  
Malignant (n = 11) 
(median age = 66) 
WDLS 5 
DDLS 2 
Angiosarcoma 3 
Inflammatory myofibroblastic 
tumour 
1 
Benign (n=5) 
(median age = 45) 
Lipoma  3 
Myxoma 1 
Leiomyoma 1 
This is a tabular summary of the characteristics of the prospective clinical cohort demonstrating 
recruitment of various STS subtypes and benign cases. 
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Table 2.3: Cell cycle arrest reagents 
Agent Mechanism of action 
Cell cycle 
arrest phase 
Range of 
concentrations 
Optimal 
concentration 
Exposure 
time 
Source 
Catalogue 
no. 
Nocodazole 
Interferes with the 
polymerization of 
microtubules 
M -Phase 500 ng/ml – 1 ng/ml 5 ng/ml 24 hrs 
Acros Organics, 
Geel, Belgium 
358240100 
Aphidicolin 
Specific inhibitor of DNA 
Polymerase-α 
G 1 - S Phase 50 µg/ml – 5 µg/ml 12.5 µg/ml 24 hrs 
Sigma Aldrich, 
St. Louis, USA 
A0781 
Hydroxyurea 
Inhibits DNA synthesis 
 
S – Phase 100 µg/ml – 5 µg/ml 25 µg/ml 48 hrs 
Sigma Aldrich, 
St. Louis, USA 
H8627 
This is a tabular summary detailing the cell cycle arrest reagents used in the study, a brief description of their mechanisms of action, the range of 
concentrations tested and the optimum concentration dose used and exposure times in cell cycle arrest experiments.  
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Table 2.4: Primary antibodies used in the study 
This is a tabular summary of the primary antibodies used in the study. † the MDM2 (2A10) Abcam 
antibody was abandoned from use in the cohort analysis after Proof of Principle experiments. 
  
Recognition Name Clonality Epitope Reactivity Source 
Catalogue 
no. 
P53 DO-7 
Mouse 
monoclonal 
IgG 
35-45 Human 
Leica 
Microsystems 
NCL-L-p53-
DO7 
MDM2 SMP-14 
Mouse 
monoclonal 
IgG 
154-167 Human 
Santa Cruz 
Biotechnology, 
Inc. 
Sc-965 
MDM2† 2A10 
Mouse 
monoclonal 
IgG 
249-339 Human Abcam Ab16895 
MDMX MDM4 
Rabbit 
polyclonal 
IgG 
125-175 Human 
Bethyl 
Laboratories 
IHC-00108 
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Table 2.5: Details of primers used in the study 
Exon Nucleotide Sequence 
Size of PCR 
Product 
Tm° 
P53 Exon 4 F: 5’–d(TCCCAAGCAATGGATGATTT) 
R: 5’–d(TTCTGGGAAGGGACAGAAGA) 
194 bp 63°C 
P53 Exon 5٭ F: 5’–d(CTCTTCCTGCAGTACTCCCCTGC) 
R: 5’–d(GCCCCAGCTGCTCACCATCGCTA) 
211 bp 55°C 
P53 Exon 6٭ F: 5’–d(GATTGCTCTTAGGTCTGGCCCCTC) 
R: 5’–d(GGCCACTGACAACCACCCTTAACC) 
182 bp 55°C 
P53 Exon 7٭ F: 5’–d(GCTTGCCACAGGTCTCCCCAAG) 
R: 5’–d(AGGCTGGCAAGTGGCTCCTGAC) 
192 bp 59°C 
P53 Exon 8٭ F: 5’–d(TGGTAATCTACTGGGACGGA) 
R: 5’–d(GCTTAGTGCTCCCTGGGGGC) 
134 bp 50°C 
P53 Exon 9٭ F: 5’–d(GCCTCTTTCCTAGCACTGCCCAAC) 
R: 5’–d(CCCAAGACTTAGTACCTGAAGGGTG) 
102 bp 50°C 
MDM2 Exon 1 F: 5’–d(TTCAGACACGTTCCGAAACTG) 
R: 5’–d(AGACACGATGAAAACTGGAAATCAT) 
263 bp 55°C 
MDM2 Exon 2 F: 5’–d(AGCACCGACTTGCTTGTAGC) 
R: 5’–d(CAGAGCCATGCTACAATTGAGG) 
296 bp 55°C 
MDM2 Exon 3 F: 5’–d(CATAATGATTAGATCCTCCCCAGCAT) 
R: 5’–d(CGACCACAAAATTAAATGTTGCTGC) 
338 bp 55°C 
MDM2 Exon 4 F: 5’–d(GTTCCTGGTTGTTTACCCCTAT) 
R: 5’–d(GAATGAGGGTAGAGGTGAACTG) 
310 bp 55°C 
MDM2 Exon 5 F: 5’–d(GAAGTCTGGTTAGATCCAGCTT) 
R: 5’–d(CCTCAGTATGTGGTTTTAGTTCATATG) 
310 bp 55°C 
MDM2 Exon 6 F: 5’–d(GCCCACCACCAAGTTTCTGA) 
R: 5’–d(GTACAAGGTCCTAAGCATTTAGGAA) 
242 bp 55°C 
MDM2 Exon 7 F: 5’–d(GGTGGGAGTGATCAAAAGGTAA) 
R: 5’–d(ACTCAGAGGTTAATTCATCTCAACC) 
365 bp 55°C 
MDM2 Exon 8 F: 5’–d(CTGCTGTAACAGTTGGACAGAT) 
R: 5’–d(CCGTATCCTTATTAGGACTGCC) 
387 bp 55°C 
MDM2 Exon 9 F: 5’–d(ACAGAGGTCAAGAGGTGATGTTTAT) 
R: 5’–d(GGCTATAATCTTCTGAGTCGAGAGA) 
(or) 
R: 5’–d(CCTCAAGTCCACAAACCAATGTGT) 
168 bp 
 
363 bp 
55°C 
MDM2 Exon 10 F: 5’–d(CCATTGTGGGTAAGGATTTCTCTC) 
R: 5’–d(GCTACAGGTCTCATCACAACAAAT) 
438 bp 55°C 
MDM2 Exon 11 F: 5’–d(AGTCCTCATGCTGTTTACAGTGACT) 
R: 5’–d(CACTATTCCACTACCAAAGTAGGTC) 
898 bp 55°C 
MDMX Exon 1 F: 5’–d(CTGCTGGTTGCCTTTGTGTG) 
R: 5’–d(GCTTCCTGCCTTGACTTCTC) 
307 bp 55°C 
MDMX Exon 1 
(transcript 3) 
F: 5’–d(GCTCAGCCTTTCTAGCTCTC) 
R: 5’–d(ACCCACCTCTCAAGCTCCTC) 
330 bp 55°C 
MDMX Exon 2 F: 5’–d(AGGCGACAGAGCAAGACCTT) 
R: 5’–d(GGAGCTTGCAGTGATCTGAG) 
1168 bp 55°C 
MDMX Exon 3 F: 5’–d(GGAGCGGCTTTCCTGTTGTA) 
R: 5’–d(CAGTGCCTCATAGGCTACCT) 
432 bp 55°C 
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MDMX Exon 4 F: 5’–d(AGATTCTGCCTTTGTATGCCTTAC) 
R: 5’–d(CCAGTCATGCCAAAGATAGCATTC) 
307 bp 55°C 
MDMX Exon 5 F: 5’–d(CTAGGGACTAAACCTGGCTC) 
R: 5’–d(ACTCTGTCCCTGGTCTGTGA) 
320 bp 55°C 
MDMX Exon 6 F: 5’–d(CACACTAACTGGTGAGCCAG) 
R: 5’–d(GGGTTGCTAAAATAGCACTACCTC) 
378 bp 61.8°C 
MDMX Exon 7 
(transcript 2) 
F: 5’–d(GGGAGGAGATTTGAGCTCTG) 
R: 5’–d(CATCTGGAAACTGAAGTTGGGC) 
535 bp 61.8°C 
MDMX Exon 8 
(transcript 2) 
F: 5’–d(TGGCGATGTAGTGTGACGAC) 
R: 5’–d(GCTTTTAAGGCAGCCCTGGTTA) 
439 bp 55°C 
MDMX Exon 9 
(transcript 2) 
F: 5’–d(AAGCTGTCTCCTTAAGTGCTAGAG) 
R: 5’–d(CAAGGTAGGGAGAGGATAAGATCAA) 
434 bp 55°C 
MDMX Exon 10 
(transcript 2) 
F: 5’–d(AGCAGTTGTGGCACTATCAGTGTA) 
R: 5’–d(CTGTTCTTCATTGTTAGCTCCAGT) 
927 bp 55°C 
This is a tabular summary of the primers used in the study. F = forward; R = reverse;  Tm° = actual 
annealing temperature used for each primer. ٭Primers were reproduced from Y Oda, 2000 (184). 
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3 Assessment of Methods 
3.1 Aims 
The aim of this Section is to examine the efficacy of the Abs utilised in this study and the 
related methodology, in detecting the relevant biomarkers by immune-staining techniques. 
The Section also includes brief examples of the optimisation of the methods experiments. 
3.1.1 Choice of Control Cell Lines 
HT29, U2OS and SW-872 cell lines were chosen as controls for the immune-staining 
experiments, as they have been widely utilised and extensively characterised regarding their 
P53, MDM2 and MDMX expression status (as shown in Table 3.1). Previous studies have 
shown that U2OS and HT29 over-expressed MDM2, whereas SW-872 had normal MDM2 
expression. U2OS over-expressed MDMX whereas SW-872 had normal expression. All three 
cell lines had expressed P53 in different intensities. Wild type P53 was retained in U2OS but 
the other two cell lines had mutant genotypes for P53. Therefore, the selected three cell 
lines provided a sufficiently diverse platform for the proof of principle experiments. 
3.1.2 Human Tissue Controls  
The following controls were included in proof of principle experiments, after being verified 
and fully characterised by a Specialist Consultant Histopathologist (Dr Will Merchant, LTHT): 
(A) Negative controls: This included 1 sample of normal fat from breast tissue and 3 
benign large lipomas, with confirmed normal MDM2 by FISH. 
(B) Positive controls: Three samples of fully characterised liposarcoma, with confirmed 
MDM2 amplification by FISH. 
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3.2 Proof of Principle Experiments 
A series of experiments were performed on control cell lines and FFPE human tissues as 
“proof of principle”. These experiments included Immunochemical staining; Western 
blotting; and Sanger sequencing of genomic DNA. 
3.2.1 Immunocytochemistry 
ICC experiments for MDM2, MDMX and P53 were performed on the control cell lines, 
according to the protocol described in Section 2.7.1. The aim was to examine the specificity 
of the primary antibodies used (refer to Table 2.4) and the reproducibility of the results 
obtained. No primary or no secondary Ab controls were included as per protocol. Examples 
of ICC results are provided in Figures 3.1 and 3.2. 
Negative staining (blue stain) was observed in all control experiments lacking primary and / 
or secondary Abs. The expression patterns of MDM2, MDMX and P53 were mosaic and 
appeared to be affected by the cell cycle phase. Strongly positive MDM2 nuclear staining 
(brown stain) was obtained in HT29 and U2OS. On the other hand, weaker and infrequent 
stain was detected in SW-872, which in this case was limited to cells undergoing division 
(mitosis). Similarly, strong positive MDMX staining was seen in U2OS but not in SW-872. All 
three cell lines stained positive for P53 with varying intensities. Reproducibility of results 
was confirmed upon repeating the control experiments. 
The ICC results obtained demonstrated high specificity of the primary Abs used as they 
agreed with what has been previously described in the literature (Table 3.1). 
3.2.2 Immunohistochemistry Control Experiments 
IHC experiments were performed on FFPE human tissue controls (Section 3.1.2) as per the 
protocol detailed in Section 2.7.2.  
These experiments showed negative nuclear stain for MDM2, MDMX and P53 proteins in all 
the 4 negative control tissues.  Positive nuclear stains for MDM2, MDMX and P53 were 
obtained in all the 3 LS positive controls (as shown in Figure 3.3).  
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IHC results correlated with the known amplification status of MDM2 by FISH. Additionally, 
intrinsic controls were demonstrated by a negative vascular endothelial stain within the 
positive control tissue slides (Figure 3.4). 
3.2.3 Influence of Cell Cycle Phase on Expression of MDM Proteins  
The ICC experiments had revealed a mosaic pattern of different MDM2 and MDMX stain 
intensities and intracellular localisations within each of the analysed cell lines. This 
observation agreed with the natural cellular behaviour of cell cycle regulatory proteins, like 
P53, MDM2 and MDMX, as the expression of these proteins may fluctuate during different 
phases of the cell cycle. To further elaborate on this observation and to examine if this 
phenomenon might influence the IHC scoring results, bearing in mind that LSs are slow 
growing tumours with limited mitotic figures, ICC analysis for MDM2 and MDMX was 
performed on the 3 control cell lines, after incubation of the tissue cultures with each of the 
cell cycle arrest agents shown in Table 2.4. The protocols for these experiments are detailed 
in Section 2.6. 
Figures 3.5 and 3.6 illustrate the staining intensities and the intracellular locations of MDM2 
and MDMX in response to cell cycle arrest reagents, respectively. Two cell lines were 
selected for the purpose of demonstration in these figures: SW-872, as it had normal 
expression of both MDM2 and MDMX; and HT29, as it over-expressed both proteins.  
3.2.3.1 MDM2 Expression Influenced by Cell Cycle Phase 
Predominantly nuclear MDM2 stain was seen in early S-phase, when cell cultures were 
under the influence of Aphidicolin. In comparison, when cell lines were held in a late S-
phase and M-phase under the influence of Hydroxyurea and Nocodazole, respectively, the 
positive (brown) stain was detected in the cytoplasm, with distinct negative nuclear staining. 
These changes were noticeable in both the intracellular localisations and the intensities of 
staining signal and they were obvious both in cells that had apparently normal MDM2 
expression (SW-872) and in those that over-expressed MDM2 (HT29, U2OS).  
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3.2.3.2 MDMX Expression Influenced by Cell Cycle Phase 
For MDMX, no substantial effects on the expression intensities or intracellular locations 
were observed in the MDMX over-expressing cell lines (U2OS and HT29) in response to the 
cell cycle arrest agents. Only weak and predominantly cytoplasmic expression was noted in 
cell lines that did not overexpress MDMX in stress-free conditions (SW-872) when subjected 
to the influence of cell cycle arrest agents. 
3.2.3.3 Implications of MDM Expressions in Response to Cell Cycle  
While the expression patterns for both MDM2 and MDMX appeared to be influenced by the 
cell cycle phase, it seemed that MDM2 was significantly more affected than MDMX. 
However, to eliminate this potential source of bias in subsequent IHC profiling experiments, 
it was decided that dividing cells (mitotic figures) would not to be included in the scoring 
protocol. 
It is noteworthy that different shift patterns of cellular MDM2 and MDMX expression were 
observed in response to the cell cycle arrest reagents. For example, Nocodazole-treated 
HT29 tissue cultures were noted to have negative nuclear MDM2 expression, but high 
nuclear and cytoplasmic MDMX. This observation confirmed lack of cross reactivity between 
the MDM2 and MDMX Abs used in the study. 
3.2.4 Specificity of Antibodies 
In order to examine the specificity of the Abs utilised in the study, Western blot experiments 
were performed in the control cell lines and FFPE tissue controls, according to the protocol 
described in Section 2.7.4. These experiments were performed to ensure that only Abs 
detecting appropriate single bands would be selected in subsequent IHC profiling 
experiments. 
3.2.4.1 Protein Quantification 
Cells were cultured and cell lysates were prepared as described in Section 2.7.3. Cell lysates 
from frozen tissues were prepared using the same buffer as that used for cultured cells. 
Protein concentration was analysed using a Bicinchoninic Acid Assay, according to the 
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protocol described in Section 2.7.3. Figure 3.7 illustrates the standard curve of the diluted 
BSA protein-gradient and the calculated protein concentrations for HT29, U2OS, SW-872 
and a LS control. Results are shown in µg/ml. Despite culturing cells to similar confluency, 
U20S contained the lowest protein content per unit volume of cell lysate. 
3.2.4.2 Western Blot Experiments 
Western blotting was performed for a mass equivalent of 20 µg of proteins per lysate, 
according to the protocol detailed in Section 2.7.4. A wide range molecular weight markers 
(Precision Plus Protein Standards – Dual colour [range: 10 – 250 kDa]) was used for MDM2 
and MDMX Abs to scrutinise their specificities.    
A- MDM2 
Two different mouse monoclonal Abs were used: Abcam (2A10); and Santa Cruz (SMP-14) 
(see Table 2.4). Figure 3.8 shows the Western blot images of these 2 Abs for the three 
control cell lines. Multiple bands were detected when Abcam (2A10) was used and a single 
band, within 10% of the predicted molecular weight of MDM2 (56 KDa) was detected with 
Santa Cruz (SMP-14). Furthermore, the band intensities with the latter Ab corresponded 
with the ICC results and agreed with the described expression level of MDM2 in U2OS and 
HT29 in previous reports (186-189). The SW-872 control, which demonstrated normal 
(weak) MDM2 expression on ICC did not show a visible band on Western blot with Santa 
Cruz (SMP-14) Ab. 
B- MDMX 
While MDMX expression levels were not previously described in HT29, cell lines SW-872 and 
U2OS were known to have normal expression levels and over-expression of MDMX, 
respectively (refer to Table 3.1). Consequently, U2OS and a fresh LS sample, from the study 
cohort, which over-expressed MDMX on IHC, were used as positive controls and SW-872 
was used as a baseline (weak) control. MDMX Western blot images obtained for these 
controls, demonstrated a single band, within 10% of the predicted molecular weight for 
MDMX (56 KDa), in positive controls and no visible band for SW-872 (Figure 3.9).  
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A single band within the predicted molecular weight range for P53 (53 KDa) was obtained 
for each of the control cell lines, when the experiment was replicated on a fresh blot, as 
seen in Figure 3.9.  
3.2.4.3 Implications of Antibody Specificity Tests  
For MDM2, Santa Cruz (SMP-14) Ab was selected for subsequent ICC and IHC optimisation 
experiments and in the analysis of the patient cohorts, since this demonstrated a single 
Western band of approximately the correct molecular weight. The Abcam (2A10) Ab was 
rejected. 
For MDMX, Bethyl Laboratories (MDM4) Ab; and for P53, Leica Microsystems (DO7) Ab were 
accepted for subsequent experiments, as they each showed a single band within 10% of the 
predicted molecular weights of their corresponding proteins.  
 
3.2.5 PCR and Gene Sequencing for MDM2 and MDMX 
3.2.5.1 Rationale 
It was important to examine if the detected MDM2 and MDMX proteins in the control cell 
lines were encoded by mutant genes, since mutations can affect the protein expression 
levels and this may potentially introduce bias in the subsequent planned experiments. 
3.2.5.2 PCR and Sanger Sequencing  
DNA was extracted from the control cell lines, as described in Section 2.7.6. All MDM2 and 
MDMX gene exons were amplified by PCR. The PCR products were purified prior to Sanger 
sequencing using the protocols described in Sections 2.7.7 and 2.7.8. 
No mutations were detected in any of the exons for MDM2 and MDMX in all three control 
cell lines. The results are not shown for abbreviation. 
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3.2.5.3 Implications of PCR and Sanger Sequencing Experiments 
As no mutations were detected in MDM2 or MDMX, in any of the control cell lines, it was 
therefore demonstrated that the Abs used in immunochemical staining experiments were 
able to detect, at least, the wild type status of MDM2 and MDMX proteins.  
3.2.6 Summary of Proof of Principle Results  
In summary, the immunochemical staining results for MDM2, MDMX and P53 in cell lines 
and FFPE blocks demonstrated a reliable sensitivity and reproducibility of results for the 
utilised Abs, as they matched what had been described in the literature. The specificity of 
the Abs was demonstrated by a single band in the Western blot analyses and the Sanger 
sequencing results provided evidence that the detected MDM2 and MDMX proteins were of 
wild type status. Consequently, optimisation of methods and subsequent implementation of 
protocols for further sample analyses in the study was considered appropriate. 
3.3 Optimisation of Methods 
As described in Section 2.7.2.1, multiple and successive steps of IHC method optimisation 
were performed leading to enhanced sensitivity and specificity of the adopted methods in 
detecting the biomarkers of interest. LS tissues are naturally sensitive and fragile due to 
their minimal stromal epithelial components. Therefore, perhaps the most critical and 
challenging optimisation step was in the antigen retrieval techniques, as briefly discussed in 
this Section below.  
Three antigen retrieval methods, utilising heat application in 10mM citrate buffer (pH 6.0) 
solution, were tried. It was noted that some conventional retrieval methods routinely used 
for other tissues, including the utility of microwave oven or pressure cooker, were too harsh 
on LSs and occasionally resulted in false positive results. Figure 3.10 illustrates false positive, 
strong MDM2 staining in the negative tissue controls (normal fat and benign lipomas), 
including non-specific positive staining of their vascular endothelium. However, when gentle 
retrieval by heated citrate buffer bath at sub-boiling temperature was employed, more 
specific nuclear staining was achieved. This has been demonstrated by no staining in 
negative controls; specific nuclear staining of lipoblasts in LS tissues; and negative staining 
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of vascular endothelium (internal controls) of examined controls. Therefore, the latter 
method was adopted in the subsequent cohort analysis experiments ensuring utility of 
negative controls with each run of IHC. 
3.4 Discussion 
3.4.1 Choice of Primary Antibodies 
The primary antibodies selected for this project have been used in related studies and have 
produced a single band in Western blots in previously published work (190-192), which has 
been subsequently confirmed by Western blot experiments in this study. The MDM2 
antibodies are sensitive to epitopes that are lost in the described non-functional MDM2 
splice variants (refer to Figure 1.3, MDM2 splice variants). The MDMX epitope recognised by 
the antibody used maps to a region between residues 125 – 175, which is lost in the 
functional MDMX-S splice variant and therefore may have resulted in under-representation 
of MDMX functional cellular abundance. While MDMX-S is estimated to be over-expressed 
in 17% of STS, its over-expression in LSs appears to be far less common (80). P53 antibody is 
sensitive to both wild type and mutant proteins. It was raised to an epitope that does not 
reside within the P53 – MDM interaction domain and therefore has the ability to detect free 
and MDM-interacting P53. 
3.4.2 Assessment of Method  
Sensitivity and specificity of the antibodies used here for detecting the relevant biomarkers 
have been demonstrated by the following criteria: 
1. Negative staining in no primary and no secondary Ab negative controls and 
reproducibility of results. 
2. Matching ICC results of the control cell lines with what has been already published in 
the literature. 
3. Satisfactory positive and negative IHC controls for benign and malignant tissues of 
confirmed MDM2 status by FISH. 
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4. Satisfactory intrinsic controls showing specific staining of tumour cells and negative 
staining of vascular endothelium within the same examined tissue slides. 
5. Distinct patterns of MDM2 and MDMX expression in cell cycle arrest experiments. 
6. Western blot analysis resulted in a single band at the expected molecular weight for 
each of the analysed proteins. Antibodies producing multiple bands were rejected.  
7. Successful optimisation of method experiments leading to increased specificity of 
IHC staining, sharper and easily interpretable results, leading to objective scoring. 
3.4.3 Choice of Scoring Protocol 
IHC assessments in this study were based on full tissue-block sections. Because the density 
of malignant cells (that are eligible for scoring) in LSs may be very low, implementing tissue 
microarray systems may not have permitted adequate scoring. While the researchers 
acknowledge the benefits of microarray-based IHC assessments in terms of experimental 
uniformity, implementation of this technique in LS tissue characterisation studies can 
potentially compromise the obtained results. Previous similar LS tissue-characterisation 
studies have also used full tissue blocks (34, 88). 
The scoring protocol employed in this study was adapted from related LS studies (90). The 
protocol took into account the diversity of LS tissue characteristics, the sporadic paucity of 
malignant lipoblasts, the potential effects of cell cycle division in over-scoring and potential 
for inter-observer discordance. Disputed cases were revised jointly by the two scorers and 
then independently proof read and re-scored by a specialist consultant histopathologist. 
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Table 3.1: Characteristics of the analysed cell lines  
Cell line Origin Genotype Phenotype Reference(s) 
U2OS 
Type: Human 
osteosarcoma 
Site: Tibia 
Ethnicity: Caucasian 
Age: 15 years 
P53 wild type 
MDM2 not amplified 
MDM2: 
over- expression 
MDMX: 
over-expression 
P53: 
over-expression 
(135, 164, 
186-188) 
SW-872 
Type: Human 
liposarcoma 
Site: Unknown 
Ethnicity: Caucasian 
Age: 36 years 
P53 mutant 
MDM2 not amplified 
MDM2: 
normal-expression 
MDMX: 
normal-expression 
P53: 
over-expression 
(188, 193) 
HT29 
Type: Human 
adenocarcinoma 
Site: Colon 
Ethnicity: Caucasian 
Age: 44 years 
P53 mutant 
MDM2 amplification 
status is unknown 
MDM2: 
over-expression 
MDMX: 
unknown 
P53: 
over-expression 
(189) 
This is a tabular summary for the relevant characteristic features of the analysed cell lines in the 
study with their related references as described in the literature. 
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Figure 3.1: MDM2 and MDMX positive and negative cell line controls  
A representative sample of cell line controls for MDM2 and MDMX. Note the negative (blue stain) in samples with no primary antibodies. Positive 
(brown stain) was seen in cell lines known to over-express MDM2 and MDMX. No brown stain was seen in negative cell line controls. All images were 
taken at 40 x magnification. 
  
 No primary antibody control Positive control Negative control  
MDM2 controls HT29 
 
HT29 
 
SW-872 
 
MDMX controls  U2OS 
 
U2OS 
 
SW-872 
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Figure 3.2: P53 cell line controls 
A representative sample of P53 cell line controls. Uniform over-expression of P53 was seen in cell lines with mutant P53 compared to wild type status. 
The figure illustrates the ability of the primary antibody to detect both mutant and wild type P53. All images were taken at 40 x magnification. 
  
 No primary antibody control P53 P53 
Wild type P53 
control 
U2OS 
 
U2OS 
 
 
Mutant P53 
controls 
SW-872 
 
SW-872 
 
HT29 
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Figure 3.3: Immunohistochemistry tissue controls  
Sample IHC results from control tissues demonstrated negative staining in normal fat and lipomas and positive staining in liposarcoma. All images were 
taken at 40 x magnification. 
 MDM2 MDMX P53 
Normal fat from 
breast tissue  
(negative control 1)  
   
Lipoma  
(negative control 2) 
   
WDLS 
(positive control) 
MDM2 amplified  
P53 wild type 
Sample no. 16 
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Tissue characteristics Intrinsic Positive / Negative controls  
WDLS 
MDM2 amplified 
MDM2 controls: 
Positive: MDM2 over-
expression 
Negative: no staining in 
vascular endothelium 
 
WDLS 
MDMX controls 
Positive: MDMX over-
expression 
Negative: no staining in 
vascular endothelium 
 
Figure 3.4: Intrinsic controls  
Illustration of intrinsic tissue controls showing positive MDM2 / MDMX staining in lipoblasts and 
negative staining in vascular endothelium (as indicated by the red arrows). Images were taken at 
60 x magnification. 
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Figure 3.5: ICC for MDM2 in different phases of the cell cycle 
Note the SW-872 DMSO control sample showing negative staining except for cells in division, the 
intensities and intracellular localities of MDM2 were affected in response to different cell cycle 
arrest reagents. All images were taken at 40 x magnification.   
Immunocytochemistry  - MDM2, cycle arrest reagents 
Agent SW-872 HT29 
DMSO control 
vehicle 
  
Aphidicolin 
Early S-phase 
  
Hydroxyurea 
Late S-phase 
  
Nocodazole 
M-phase  
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Figure 3.6: ICC for MDMX in different phases of the cell cycle.  
SW-872 showed weakly positive cytoplasmic stain in response to cell cycle manipulation. Note 
how the strongly positive HT29 remained non affected by the cell cycle arrest reagents. All images 
were taken at 40 x magnification. 
  
Immunocytochemistry  – MDMX, cell cycle arrest reagents  
Agent SW-872 HT29 
DMSO control 
vehicle 
  
Aphidicolin 
Early S-phase 
  
Hydroxyurea 
Late S-phase 
  
Nocodazole 
M-phase 
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Figure 3.7: Protein quantification in cell lysates 
Adjusted linear curve from standard protein concentration gradient showing the calculated 
protein concentrations of the analysed samples. 
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MDM2 Abcam (2A10) MDM2 Santa Cruz (SMP-14) 
  
Figure 3.8: Western blot images for MDM2 
Western blot images for different MDM2 antibodies demonstrating multiple, nonspecific bands 
with Abcam (2A10) Ab, compared to single band within 10% of predicted molecular weight of 
MDM2 when using Santa Cruz (SMP-14) Ab. The arrows indicate the predicted location of MDM2 
band within the molecular weight ladder. Note the higher intensity of HT29 band similar to ICC 
scores and no band was seen in the base line (weak) control cell line (SW-872)when Santa Cruz 
(SMP-14) Ab was used. L1 = ladder1 (Pre-stained Protein Marker); L2 = ladder2 (Precision Plus 
Protein Standards). Wider range molecular weight markers were intentionally used for MDM2 and 
MDMX study-approved Abs to confirm their specificities.  
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MDMX (Bethyl Laboratories [MDM4]) P53 (Leica Microsystems [DO7]) 
  
Figure 3.9: Western blot images for MDMX and P53 
Western blot images for MDMX and P53 showing visible bands within 10% of the predicted 
molecular weights. The arrows indicate the predicted location of the protein within the molecular 
weight ladder. Note no band was detected for MDMX in SW-872 cell line. A high Intensity P53 
band in HT29 similar to its ICC results. LS1, liposarcoma control case; . L1 = ladder1 (Pre-stained 
Protein Marker); L2 = ladder2 (Precision Plus Protein Standards). Wider range molecular weight 
markers were intentionally used for MDM2 and MDMX study-approved Abs to confirm their 
specificities. 
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Method Normal fat from breast tissue Lipoma Liposarcoma  Comments 
A-
Microwave 
oven heat 
application 
at 800 
watt in for 
10 minutes    
Non-specific 
staining including 
vascular 
endothelium, 
false positives in 
fat and lipoma 
B- 
Pressure 
cooker 
retrieval 
for 2 
minutes 
   
Unanimous non-
specific staining, 
false positives in 
fat and lipoma  
C-Gentle 
retrieval in 
hot bath at  
(95-98 °C) 
for 20 
minutes 
   
Preserved tissue 
architecture, 
specific staining, 
adequate 
negative and 
internal controls 
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Figure 3.10: Antigen retrieval examples for MDM2 
Illustrative example of different antigen retrieval techniques. All methods used 1mM citrate buffer solution (pH 6.0). Note a false positive MDM2 
staining, including a vascular endothelium, in negative control samples (normal fat and lipoma) when microwave oven heat and pressure cooker 
methods are applied. Specific nuclear staining in LS positive control was obtained with satisfactory negative controls (including negative vascular 
endothelium) when gentle retrieval in hot citrate buffer bath was used.
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4 Immunohistochemical Profiling of Liposarcoma  
4.1 Aims  
The primary aim of this Section is to describe the expression profiles of MDM2, MDMX and 
P53 in different subtypes of LS, and to examine the effect of MDM2 and MDMX co-
expression on P53. 
The secondary aims are to assess the correlation between MDM2 amplification and over-
expression, and explore the value of IHC, as a complementary tool to FISH, in making the 
diagnosis of WDLS and DDLS.  
4.2 Cytogenetic Results in Liposarcomas 
Cytogenetic analysis was performed by the Yorkshire Regional Genetics Services, as 
described in Section 2.9. The results were retrieved and analysed by the researcher. 
Cytogenetic testing (G band analysis and / or FISH) was attempted in 60 of the 64 LS cases in 
the cohort. It provided additional molecular data to the histopathologist to aid the diagnosis 
in 55 cases and completely failed in 5 cases (92% success rate). Failure to provide 
interpretable results was largely due to inadequate primary cell culture growth, required for 
metaphase spread in G band analysis, or due to overgrowth of fibroblasts and other normal 
cells. Occasionally FISH analysis failures were from low numbers of malignant cell in the LS 
sections provided to the Cytopathologist. An example of cytogenetic analysis results is 
provided in Figure 4.1. A summary of the cytogenetic results of the liposarcoma cohort 
analysed here is presented in Table 4.1 and any variations specific to a subtype are 
described below.  
Cytogenetic analysis was attempted in 10 of the 12 MXLS-RCLS cases and completely failed 
in one case. The majority of the successfully-analysed MXLS-RCLS cases (n=7/9) displayed 
the characteristic chromosomal translocation t(12;16)(q13;p11). However, one case 
displayed multiple complex translocations and another showed a probable MDM2 
amplification. 
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Cytogenetic analysis was attempted in all but one of the 43 WDLSs and failed in 3 cases. It 
confirmed the diagnosis of WDLS by a detected MDM2 amplification in 33 of the 39 
successfully-analysed cases. However, it revealed some inconsistencies between the 
histological diagnosis and the molecular features in 6 cases, as FISH analysis in these failed 
to show the characteristic MDM2 amplification to support the histological diagnosis. In 
contrast, all DDLSs analysed by FISH (n=7) had MDM2 amplification. 
This study identified four WDLSs and two DDLSs that had apparently normal karyotyping by 
G band examination and were not originally subjected to FISH analysis to examine for 
MDM2 amplification. These cases underwent specialist review and subsequent FISH analysis 
on their stored tissue blocks at the Pathology Department, LTHT. FISH analysis of these 
cases revealed MDM2 amplification in the DDLSs and in 2 of the 4 WDLSs. 
Collectively, successful cytogenetic analysis confirmed the histological diagnosis in 48 of the 
attempted 60 cases (80%); provided results inconsistent with the histological features in 7 
cases (12%); and failed to provide results in 5 cases (8%).  
4.2.1 Correlation between MDM2 Amplification and Over-Expression 
78% of all WDLS and DDLS that demonstrated amplification of the MDM2 gene by FISH 
showed MDM2 over-expression on subsequent analysis (n=31/40). On the other hand, all 6 
WDLSs with no apparent MDM2 amplification by FISH were found to have over-expressed 
the MDM2 protein. A contingency table of MDM2 amplification and MDM2 over-expression 
is provided in Table 4.2. 
4.3 Subtype – Specific Expression Profile of Liposarcomas 
Sixty four, histologically-characterised, LS cases were analysed by IHC (Table 4.3) according 
to the protocols detailed in Section 2.7. These comprised the following sub-types: WDLS 
(n=43) including 1 case of inflammatory and 1 case of mixed differentiation; DDLS (n=9); and 
MXLS-RCLS (n=12). The subtype-specific expression levels of each of the analysed proteins 
are demonstrated in Figure 4.2. 
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4.3.1 Well-Differentiated Liposarcomas 
77% (33/43 cases) of WDLS over-expressed MDM2, mostly at high intensity (++ score = 56%) 
with a median MDM2 score of 43. Co-expression of MDMX was seen in 56% of all cases, as 9 
of the 33 cases that over-expressed MDM2 did not co-express MDMX. The solitary MDM2 
over-expression was not featured in the other LS subtypes. MDMX expression was not only 
less frequent than MDM2 in WDLS but also had lower scores per individual case. Only 10 
cases scored (++), with a median MDMX score of 14. 
10 cases had apparently diminished expression levels of both MDM2 and MDMX. This 
expression profile mainly correlated with normal P53 expression. However, two of these 
cases showed P53 over-expression, suggesting a possible P53 mutation.  
P53 over-expression was seen in 26% of cases (n=11). Excluding the two cases mentioned 
above that had normal MDM2 and MDMX, P53 over-expression was mainly detected in 
cases that co-expressed both MDM2 and MDMX in abundant levels (++).  
A trend of normal (low) cellular expression of P53 was largely observed in cases that over-
expressed MDM2 solely (n= 8/9) or in association with MDMX, where the relative 
expression levels of the MDM2 were significantly higher in relation to MDMX (n=14/14). 
4.3.2 De-Differentiated Liposarcomas 
All 9 cases of DDLS showed MDM2 and MDMX over-expression, in relatively high intensities.  
The expression level of the two proteins was comparable to one another with a median 
MDM2 score of 92 and MDMX score of 60. Both median scores are within the (++) 
stratification of the scoring protocol.  
P53 over-expression was seen in 7 of these cases (78%). The two cases that did not over-
express P53 had relatively higher expression levels of MDM2 in relation to MDMX. This 
observation is in agreement with the P53 expression trend noted in WDLS. 
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4.3.3 Myxoid - Round Cell Liposarcomas  
The majority of the 12 MXLS-RCLS had positive MDM2, MDMX and P53 staining. A 
predilection to over-express MDMX at higher relative levels, compared to other LS subtypes, 
was noted with a median MDMX score of 88.5 and median MDM2 score of 84.5. Ten of 
these cases also had positive P53 expression (83%). Only 1 case had apparently normal 
expression of the three proteins. Round cell de-differentiation was detected histologically in 
3 cases. It did not influence the staining pattern. 
4.3.4 All Liposarcoma Subtypes  
As shown in Table 4.3, MDM2 over-expression (+/++) was detected in 83% of cases 
(n=53/64). MDMX co-expression (+/++) was seen in 69% of cases (n=44/64) in varying ratios 
compared with MDM2. The co-expression pattern was subtype-dependent. WDLS displayed 
abundant levels of MDM2 in relation to MDMX, whereas all other subtypes had comparable 
levels of MDM2 and MDMX expression. No solitary MDMX (without MDM2) over-expression 
was detected in any of the analysed cases. 44% of cases (n=28/64) had positive P53 
expression (+). Perhaps unexpectedly, most of these cases (n=25/28) co-expressed both 
MDM2 and MDMX as well. 
4.4 Analysis of Results and Discussion 
Due to real challenges in attaining accurate histological diagnoses in some LSs, it has been 
an acceptable practice for pathologists to stream their diagnoses into: certain; probable; 
and possible categories, based on the index of suspicion provided by the clinical and the 
histological features. This approach is subjective and the proportion of cases allocated into 
these categories is related to the experience and the expertise of an individual pathologist. 
However, this streaming provides a practical tool to the certainty of the diagnosis, which is 
used in daily practice (194). The practice at LTHT adopts the safest approach principle and a 
patient’s diagnostic coding of LS may be based on reasonable clinical and histological 
suspicions in some instances. 
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4.4.1 Discrepancies between Histological and Molecular Diagnostic Features 
The integration of molecular analysis into the diagnostic classification of LSs has added a 
valuable tool to the provision of a more accurate histological diagnosis. However, this 
integration has its own imperfections: the success rate to provide an interpretable result is 
approximately 90% (a similar rate was seen in this study); and the results obtained may not 
always match the given histological diagnosis, which may occasionally provide an additional 
source of diagnostic conflict. Therefore, it has been accepted that the input from molecular 
analysis may confirm a malignant diagnosis but will not provide a gold-standard alternative 
to the classical morphological histological diagnosis made by a specialist pathologist. This 
consensus is practiced at the MDT meeting of the Sarcoma Department at LTHT. In fact, it is 
also clearly documented in a recent review that involved 763 STSs including 220 LSs. The 
review showed MDM2 amplification in 96% of cases where the histological diagnosis was 
“certain” and in 79% in those where the diagnosis was “probable” (194). In contrast, a 
separate review of 50 LSs has revealed 50-70% concordance between histological diagnosis 
and molecular analysis (81). Such variations may represent the natural spectrum of 
diversities in LSs and the genuine challenge to establish a clear and objective distinction 
between certain types of benign lipomatous tumours and certain subtypes of LS (mainly 
WDLS). 
Upon reviewing the relevant literature, as summarised in Table 4.4, some studies report 
identifying WDLS and DDLS cases that lack MDM2 amplification. Collectively, these account 
for about 8% of cases. This is comparable with the findings of our study, as MDM2 
amplification was seen in 73% of the successfully-analysed WDLS and DDLS. Discrepancies 
between the histological and molecular findings were identified in 7 cases among all LS 
subtypes of the analysed cohort. Most of these discrepancies (6 of 7 cases) were, 
unsurprisingly, among the WDLS subtype as these tumours are the closest mimickers of 
benign lipomas in their histological appearance and occasionally their clinical behaviour. 
Five of these 6 cases presented in the extremities and one in the chest wall. They were 
relatively smaller in size compared to the remainder of WDLSs cases in the cohort, with a 
median size of 234 cm
3
, compared to 1080 cm
3
 for WDLSs with MDM2 amplification. In 
depth analysis, revealed that one of these cases had chromosome 12 gain (4x) where MDM2 
maps; and 2 cases had a somatic P53 mutation (as will be discussed in Section 5.4). These 
 85 
changes may present the driving force for carcinogenesis in this specific cohort. Polyploidy 
of chromosome 12 has been previously reported in LS (195). The other discrepancy was 
seen in a MXLS that presented in the retroperitoneum and demonstrated a possible MDM2 
amplification. However, the molecular findings were not certain in this case.  
All these 7 cases underwent an independent review by a specialist histopathology 
consultant outside the research group. Additionally, further cytogenetic testing including 
13q deletion, which is a characteristic of benign and low-malignant lipomatous tumours 
(196), was performed on the archival tissue blocks, to aid the revised diagnosis. Three cases 
were found to have 13q deletions of which two may be alternatively pleomorphic or 
spindle-cell lipomas. However, the site of presentation (thigh) is extremely rare for such 
tumours. Diagnoses of the other four cases remained unchanged after the review. Table 4.5 
summarises the key features of these cases. 
It is worth mentioning that the status of MDMX amplification was not assessed in the 
tumours in our study and we are not aware of any preceding published reports that 
characterised LS in this aspect. However, MDMX amplification and over-expression, without 
a concomitant MDM2 amplification or P53 mutation, has been reported, as the potential 
driving mechanism of transformation, in a subset of Glioblastomas (197). It may be 
legitimate to ask if a similar subset of cases exists within LSs, especially since two of the 
MDM2 non-amplified WDLS cases over-expressed MDMX. 
4.4.2 MDM2 Amplification to Overexpression 
Gene amplification can result in MDM2 or MDMX protein over-expression. The relevant 
literature review (Table 4.4) showed that approximately 80% of WDLS and DDLS, including 
those with confirmed MDM2 amplification, were found to over-express MDM2 protein. 
These findings are in agreement with the results of this study (Table 4.2). 
Similarly, many tumours over-express MDM2 and MDMX without increased copy numbers. 
These include: retinoblastoma (198); melanoma (84); Ewing sarcoma (192); and colon 
cancer (146). In our study, all WDLS cases without MDM2 amplification, over-expressed 
MDM2 (n=6). This may emphasise the complementary role of IHC in obtaining an accurate 
diagnosis and suggests that different mechanisms may have triggered the protein over-
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expression, other than amplification. Therefore, assessment of tumours based on gene 
amplification alone may underestimate the numbers of cases in which MDM2 and / or 
MDMX over-expression contributes to cancer initiation and progression. Consequently, it 
may underestimate the potential candidates for selective blocking strategy treatments 
based on MDM / P53 interactions. 
4.4.3 MDM / P53 Expression Profiles 
In agreement with previous reports (90, 199), MDM2 over-expression was frequently 
detected across the various subtypes of LS. MDMX co-expression was also a common 
feature and probably more frequent than previously reported (80, 118). However, the 
previous reports on MDMX expression had relatively limited numbers of LSs within their STS 
cohorts (n=18 and 37, respectively) and they were mainly focused on MDMX-S splice variant 
as a prognostic indicator. At the time of writing this report, we were not aware of any large 
study that described MDMX expression patterns in LS to compare our results with. 
A previous analysis that included 74 LSs has reported 96% IHC positivity (>10% of cells) for 
MDM2 and P53 in retroperitoneal WDLS and DDLS, compared to only 33% in non-
retroperitoneal LSs of the same histological subtypes (34). This observation was not 
replicated in our study, as no specific patterns of MDM2, MDMX or P53 expression, in 
relation to their anatomical distribution, were observed in our cohort (Table 4.6). This 
variation may be explained by the discrepancies in the antigen retrieval techniques, the 
primary Abs used and the scoring systems employed. Whereas retroperitoneal LSs generally 
have a worse prognosis, this is believed to be due to late presentation and difficulty in 
obtaining clear microscopic margins surgically (200). To explore whether distinct 
phenotypical characteristics are retained in retroperitoneal LSs that would make them more 
aggressive, may prove to be a complex task with multiple variables, which is beyond the 
scope of this study. 
As MXLS-RCLS feature cytogenetic alterations that do not implicate amplification or direct 
alterations to MDM2 or MDMX genes, previous studies regarding the expression levels of 
these proteins are limited and often MXLS - RCLS subtypes are excluded from LS 
immunohistochemical characterisation studies for the same reason (201). However, the 
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available results from the literature, regarding MDM2 over-expression in MXLS are 
essentially inconsistent. Some studies claimed normal MDM2 expression in all these cases 
(34, 88) (n=26 and 23, respectively) and others reported over 50% incidence of MDM2 over-
expression (90, 199) (n=8 and 8, respectively). However, a more recent report that analysed 
56 cases of LS with myxoid stromal features has shown MDM2 over-expression in 95% of 
cases (202). These differences may also be explained by the use of different, relatively new, 
primary Abs and the alterations in the IHC techniques. On the other hand, they may be 
genuine manifestations of tumour and intra-tumour heterogeneity (203) or genetic 
variations amongst the population of these subtypes of cancers, including MDM2 
amplification, which was reported in 14% of MXLS in a previous study that included 22 cases 
(81). The results of our study are consistent with higher expression of both MDM2 and 
MDMX proteins. Again, no previous analysis has described MDMX expression pattern in 
MXLS-RCLS subtypes. 
The described pattern of MDM2 and MDMX co-expression in the different subtypes of LS, 
was analysed further. The results confirmed that the same cases expressed the two proteins 
concomitantly, as shown in the following scatter plots (Figure 4.3), representing the actual 
expression values of MDM2 and MDMX across the different subtypes of LS. 
The observation of MDMX co-expression with MDM2 may invite further in-depth analysis of 
the dynamic, complex interactions between these proteins and their effect on P53. The co-
expression pattern, commonly seen in WDLS, in which MDM2 levels are higher in relation to 
MDMX (MDM2 : MDMX ratio >1) agrees with the previously-described cytological 
interactions between the two proteins, where MDMX increases the short half-life of MDM2 
(105) and in turn, MDM2 degrades MDMX (134). However, the observed comparable 
expression levels of the two proteins in DDLS and MXLS-RCLS may, in turn, represent how 
the ability of MDM2 to degrade MDMX becomes futile beyond a certain threshold of activity 
(135). This observation, therefore, invites further assessment to elaborate the precise 
MDM2 activity in these subtypes. 
In this study, MDM2 and MDMX co-expression was noted to correlate with the expression 
levels of P53 in two distinct patterns as shown in Figure 4.4:  
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A) A collaborative pattern: where diminished or no P53 expression was detected. This 
pattern was mainly observed in cases where MDMX was co-expressed with MDM2 but at 
relatively lower levels (+) (represented in Table 4.3 by the blue cell). This pattern could have 
resulted from MDMX collaborating with MDM2 to inhibit P53 by targeting it for degradation 
and leading to diminished P53 expression, in line with MDMX acting as an MDM2 stabiliser. 
Tumours with this expression pattern may respond well to MDM2 blockers or dual 
specificity antagonists of higher MDM2 affinity.  
B) A competitive pattern: where higher scores of P53 were observed (>10% of cells). This 
pattern was mainly noted in cases where MDMX was co-expressed at relatively high levels 
(++) (represented in Table 4.3 by the pink cell). This pattern may be explained by MDMX 
possibly “competing” with MDM2 in binding to P53, resulting in reduced P53 degradation by 
MDM2 and therefore higher cellular expression levels, in line with MDMX acting, here, as a 
P53 stabiliser (137, 204). Tumours that express this profile may best be targeted by dual 
blocker compounds. One could argue that MDMX single affinity blockers may have a 
reduced therapeutic potential in these cases, as the resulting MDMX-freed P53 may then be 
subject to degradation by the over-expressed MDM2, if no MDM2 antagonist is used in 
conjunction.  
As no cases of LS that over-expressed MDMX exclusively (in the absence of MDM2) were 
detected, there must be questions about the utility of single affinity MDMX blockers in LS. 
However, antagonising MDMX-mediated P53 suppression may still have some beneficial 
therapeutic effect in these cases and functional studies will be needed to clarify this. 
These observations regarding patterns of co-expression are in agreement with the 
previously described mutual dependence model from modified cell lines (105). 
Furthermore, a recent review recognised the emerging awareness of the significance of the 
cellular proportions of MDM2 and MDMX to each other in determining P53 stability and 
activity (138). Despite the different genetic alterations involved in the malignant 
transformation of the different sub-types of LS, it is noted that the expression level of P53 
was largely affected by the MDM2/MDMX ratio in all sub-types, with a statistically 
significant negative correlation between MDM2/MDMX ratio and P53 expression (co-
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relation coefficient = -0.437, p<0.001). P53 expression in relation to the 
Log2(MDM2/MDMX) scores is illustrated in Figure 4.5. 
The subset of cases that did not over-express MDM2 or MDMX had apparently normal 
expression levels of P53 (n=9/11). This may indicate that the P53 - MDM pathways were 
intact in these cases and therefore the biomarkers remained at low levels. In turn, this 
might suggest a different mechanism of carcinogenesis in these cases. 
Collectively, the observations made in this study invite careful characterisation of MDM2, 
MDMX and P53 proteins in tumours when considering in-vivo experimental evaluation of 
novel MDM2-specific or dual target MDM2/MDMX blocking compounds. 
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Table 4.1: Summary of the cytogenetic results for the liposarcoma cohort 
Cytogenetic analysis WDLS 
(n=43) 
DDLS 
(n=9) 
MXLS-RCLS 
(n=12) 
Not attempted 1 1 2 
Failed 3 1 1 
MDM2 amplification 
by FISH 
+ve 33 7 1(Probable) 
-ve 6 0 8 
No. of 
analysed 
cases 
39 7 9 
Chromosomal 
translocation by G 
band analysis and / or 
FISH 
+ve 0 0 8 
-ve 4◊ 2* 1† 
No. of 
analysed 
cases 
4 2 9 
Findings confirming the 
histological diagnosis / total of 
successfully analysed cases 
33/39 7/7 8/9 
This is a tabular summary of the cytogenetic analysis tests that were conducted in the LS cohort. 
The data presented is a summary from analysing the cytogenetic results for each specimen as 
provided by the Yorkshire Regional Genetics Services. The methods used for cytogenetic analyses 
are detailed in Section 2.9. 
The majority of the successfully-analysed cases (48/55) had concordant histological diagnosis and 
molecular features. Some inconsistencies were seen in WDLS.
◊ 
Two of these cases had MDM2 
amplification by
 
FISH analysis. * These two cases showed MDM2 amplification. † This case had a 
probable MDM2 amplification. +ve = positive, -ve = negative.  
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Table 4.2: Contingency table of MDM2 amplification and MDM2 over-expression 
 
 
 
 
 
 
A contingency table demonstrating the correlation between MDM2 amplification and over-
expression in WDLS and DDLS. Total number of WDLS and DDLS that were successfully analysed by 
FISH for MDM2 amplification (n=46). MDM2 protein over-expression (+/++) was determined by 
IHC and was based on the scoring protocol as detailed in Section 2.7.  
 
  
  
 
 
 
Yes No Total 
Yes 31 9 40 
No 6 0 6 
Total 37 9 46 
MDM2 over-
expression  
MDM2  
amplification 
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Table 4.3: Stratified score summary of the analysed cohort 
 MDMX - MDMX + MDMX ++ 
Total 
 P53 - P53 + P53 - P53 + P53 - P53 + 
MDM2 - 9 2 0 0 0 0 11 
MDM2 + 4 1 4 0 0 2 11 
MDM2 ++ 4 0 12 1 3 22 42 
Total 20 17 27 64 
Immunohistochemistry scores for MDM2 and MDMX were stratified as follows: (-) normal 
expression: when <11% of cells had positive nuclear staining; (+) moderate over-expression: when 
11 – 40% of cells had positive nuclear staining; (++) strong over-expression: when >40% of cells 
had positive nuclear staining. Scores for P53 were: (-) negative expression: when ≤10% of cells had 
positive nuclear staining; (+) positive expression: when 11% or more of cells had positive nuclear 
staining. 
Colour codes: Yellow cell = negative staining for both MDM2 and MDMX; blue cell = co-expression 
of MDM2 and MDMX where higher MDM2 expression levels were seen compared to MDMX 
(Pattern –A) note mostly diminished levels of P53 were seen in this group; pink cell = co-
expression of MDM2 and MDMX at proportionate levels (Pattern –B) note the associated positive 
expression of P53 in this group. 
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Table 4.4: FISH and IHC as diagnostic tools for WDLS and DDLS 
 WDLS DDLS Lipoma 
Ref. 
 
No. 
of 
cases 
FISH(+) IHC(+) 
No. 
of 
cases 
FISH(+) IHC(+) 
No. 
of 
cases 
FISH(+) IHC(+) 
 19 0/0† 19/19 10 0/0† 9/10 17 0/6 † 7/17 (90) 
 48 47/48 10/48 5 5/5 5/5 25 ND 0/25 (88) 
 27 4/5† 26/27 14 4/8 † 9/14 24 0/0† 0/24 (34) 
 91 85/91 ND 64 60/64 ND 0 0 0 (194) 
 44 41/41 44/44 61 53/55 58/61 49 0/0 3/49 (33) 
 52 41/52§ ND 0 0 0 324 7/324§ ND (205) 
 5 5/5 ND 8 8/8 ND 23 0/0 ND (206) 
Total 286 223/242 99/138 162 130/140 81/90 462 7/330 10/115  
%  92% 71%  93% 90%  2% 7%  
This summary review of published literature indicates a marginal superiority for FISH as a 
diagnostic tool for WDLS and DDLS compared to IHC. It reveals the imperfections in both methods 
as diagnostic tools (no 100% results). † Test was done in selective or controversial cases; some 
studies subsequently changed the code of diagnosis based on FISH results as indicated by §. ND = 
not done. 
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Table 4.5: Characteristic features of liposarcomas with inconsistent FISH analysis 
Age/ 
Gender 
Site of 
tumour 
Size 
cm 
First 
diagnosis 
MDM2 status 
by FISH 
P53 
mutation 
IHC
 
MDM2 
IHC 
 
MDMX 
IHC 
 
P53 
Requested 
further tests 
Second 
diagnosis after 
review 
85 / F Lower limb 6*6*3 WDLS Not amplified D184N 84 70 62 13q deletion Favours WDLS 
73 / F Lower limb 10*10*6 WDLS 
Not amplified 
but 4X gain 
Not done 32 18 1 None Unchanged 
67 / M Lower limb 14*8*7 WDLS Not amplified 
None 
detected 
25 5 46 13q deletion ?PML 
62 / M Lower limb 15*10*3 WDLS Not amplified Not done 80 32 6 13q deletion ?PML 
53 / F Upper limb 5*3*2 
WDLS - 
Inflammatory 
Not amplified Lys292*FS 70 80 32 
G band normal 
No 13q deletion 
Unchanged 
61 / M Chest wall 4*2*2 WDLS Not amplified Not done 95 85 67 
G band normal 
No 13q deletion 
Unchanged 
51 / F Lower limb 20*8*8 MXLS 
Possible 
amplification 
Not done 99 46 32 None Unchanged 
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A tabular summary of the key clinical and molecular features of the identified LS cases with inconsistent cytogenetic findings. Note that all cases 
presented in the lower limb and they were relatively small in size. The detected P53 mutation and the presence of multiple copies of chromosome 12 
may provide an alternative explanation to the driver of oncogenic changes. All cases had high expression of MDM2 on immunohistochemistry analysis 
indicating a possible complementary role in diagnosis in these controversial cases.
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Table 4.6: Immunophenotype of liposarcomas in relation to their anatomical location 
LS 
subtype 
Number 
of cases 
Retroperitoneal Non-retroperitoneal 
MDM2(+/++) MDMX(+/++) P53(+) MDM2(+/++) MDMX(+/++) P53(+) 
WDLS 43 7/7 4/7 2/7 27/36 20/36 10/36 
DDLS 9 7/7 7/7 5/7 2/2 2/2 2/2 
MXLS-
RCLS 
12 1/2 1/2 1/2 8/10 10/10 9/10 
No variations were detected in the expression profiles of the analysed proteins in relation to the 
anatomical location of LS. 
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A- 
FISH analysis of 
interphase cell 
demonstrating MDM2 
amplification, note high 
red signal in relation to 
green. 
 
B- 
Karyotype analysis 
showing ring 
chromosome 12 
(indicated by arrow) 
 
C- 
Karyotype analysis 
showing giant 
chromosome 12 (A)and 
ring chromosome (B) 
 
Figure 4.1: Examples of characteristic cytogenetic alterations in liposarcomas 
Illustration of different cytogenetic alterations commonly seen in liposarcomas. A- FISH analysis of 
interphase cell. The red probe hybridises to MDM2 and the green probe to chromosome 12 
centromere as control. B and C- chromosomal spread showing ring chromosome 12 (B) and giant 
chromosome 12 (C) using MDM2 red probe.  Images were provided by Dr Paul Roberts, Yorkshire 
Regional Genetics Services.  
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Figure 4.2: Subtype-specific expression levels of MDM2; MDMX; and P53  
The box plots above illustrate the median score (lined); interquartile range (boxed); and the 
minimum to maximum score values (whiskers) for MDM2, MDMX and P53 in subtype-specific 
categorisation. All proteins were expressed at higher levels in DDLS and MXLS-RCLS compared to 
WDLS. MDM2 expression was higher in relation to MDMX in WDLS whereas both MDM2 and 
MDMX had comparable expressions in DDLS and MXLS-RCLS. P53 expression was increased with 
increasing MDMX. IHC = immunohistochemistry.  
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Figure 4.3: Co-expression patterns of MDM proteins in different subtypes of liposarcomas 
The scatter plots above illustrate the co-expression values for MDM2 and MDMX in the various 
subtypes of LS. Different patterns of MDM2/MDMX expression levels were noted. A predilection 
to over-express MDM2 at higher levels in comparison to MDMX was a feature of WDLS, whereas 
all other LS subtypes had comparable MDM2 to MDMX expression levels on 
immunohistochemistry. The scatter plots demonstrate that the same individual cases often 
expressed both proteins. Data presented are the mean of the individual scores by two 
independent scorers. 
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Figure 4.4: Immunohistochemistry patterns for MDM2, MDMX and P53 
Three distinct patterns of immunohistochemistry staining were identified: normal expression 
where none of the examined proteins was over-expressed; negative P53 expression with higher 
scores of MDM2 in comparison to MDMX (Pattern-A); positive P53 expression with comparable 
scores of MDM2 and MDMX (Pattern-B).
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Figure 4.5: P53 expression in relation to the Log2(MDM2/MDMX) scores in liposarcomas 
The scatterplot above illustrates the P53 scores in relation to MDM2:MDMX ratio (expressed as log 2 [MDM2:MDMX] for range adjustment). The dotted 
line represents the 10% cut off value for positive P53. Across various subtypes of LS, higher P53 expression levels were detected when MDMX was co-
expressed at comparable or higher levels in relation to MDM2 (Log2[MDM2:MDMX]<1). Diminished P53 expression was noted when MDM2 was 
expressed at significantly higher levels than MDMX (Log2[MDM2/MDMX]>1).
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5 Genetic Analysis of P53 
5.1 Aims  
The aim of this Section is to assess if the detected P53 over-expression in the analysed 
cohort resulted from a somatic mutation rather than a genuine manifestation of P53 
interaction with its cellular regulators. Sanger sequencing DNA analysis of P53 was 
performed in 26 LSs of the total 28 cases that over expressed P53 in the described cohort, in 
addition to a subcutaneous lipoma that had normal P53, MDM2 and MDMX expression 
profile as a control sample.  
5.2 DNA Extraction 
Genomic DNA extraction from FFPE tissue and cell lines was performed according to the 
protocol in Section 2.10.1. Subsequently, the DNA concentration was quantified using the 
nanodrop technique and visualised with ethidium bromide following agarose gel 
electrophoresis (1% w/v agarose). Figure 5.1 shows a typical agarose gel visualisation of 10 
genomic FFPE DNA samples. Samples that failed to yield suitable DNA matter were re-
extracted until a satisfactory product was obtained. 
5.3 Polymerase Chain Reaction 
PCR amplification of P53 exons 4 to 9 was performed in 26 samples. The presence of an 
amplicon of the correct size was verified by agarose gel electrophoresis. PCR amplification 
was successful in all cases but failed for exon 7 in three of these cases (case numbers: MR1, 
MR8 and WD31), despite frequent attempts. Examples of PCR amplicon visualisation by 
ethidium bromide following agarose gel electrophoresis are shown in Figure 5.2. 
PCR amplicons were purified from unincorporated oligonucleotide primers using GenElute 
PCR clean up kit, according to the protocol in Section 2.10.2. Confirmation of retained 
amplicons post purification was performed by nanodrop and standard agarose gel 
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electrophoresis. Examples of post purification amplicon visualisation by ethidium bromide 
following agarose gel electrophoresis are shown in Figure 5.3. 
5.4 Somatic Mutations of P53 
Sanger sequencing DNA analysis was performed according to the protocol in Section 2.10.3. 
The presence of a sequence variant was identified by the visualisation of a variant peak and 
the corresponding decrease in the height of the wild type nucleotide peak when present. 
Table 5.1 summarises the detected P53 somatic mutations in the analysed cohort in terms 
of nucleotide and amino acid changes. 
Five of the 26 cases (19%) were found to have previously-described pathological somatic 
heterozygous mutations: 1 missense mutation in exon 4, c.137C>T; p.Ser46Phe (Figure 5.4) 
in a MXLS that over-expressed MDM2 and MDMX (case no. MR1); 3 missense mutations in 
exon 5 namely c.392A>G; p.Asn131Ser (Figure 5.5) and c.511G>A; p.Glu171Lys (Figure 5.6) 
in a WDLS case that expressed normal levels of MDM2 and MDMX (case no. WD28); and 
c.550G>A; p.Asp184Asn (Figure 5.7) in two cases (MXLS and WDLS), which over-expressed 
both MDM2 and MDMX (case numbers MR8 and WD42). 
A frame shift mutation was detected in exon 8, Lys292*FS (c.876DelAG) (Figure 5.8) in an 
inflammatory WDLS that also over-expressed MDM2 and MDMX (case no. WD39) . Table 5.2 
summarises the clinical, histological and molecular features of these tumours. 
Additionally, a nucleotide variant was found in exon 7, c.770T>A; p.Leu257Gln - rs28934577 
(Figure 5.9), in sporadic cases including the control lipoma. 
5.5 P53 Arg72Pro Polymorphism - rs1042522 
A single nucleotide polymorphism (SNP) C>G at exon 4, codon 72, in the proline-rich domain 
of P53, which replaces arginine (Arg) with proline (Pro), has been reported to affect P53 
functions. The Arg72 variant was found to induce apoptosis markedly better (121) and was 
linked to superior response to conventional chemotherapy, compared to the Pro72 variant 
(207). In light of these findings, this polymorphism was examined in the cohort of cases that 
over-expressed P53. The majority of cases were homozygous for the Arg72 variant (58%), 9 
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cases were found to be heterozygous and two cases were homozygous Pro72. The SNP’s 
genotype is indicated in Table 5.1 while the electropherograms in Figure 5.10 illustrates 
examples of sequences for each of the variant genotypes. 
5.6 Analysis of Results and Discussion 
The sequence analysis of TP53 encompassed all of the previously-described P53 mutational 
hot spots found in all cancer types, as identified on the P53 International Agency for 
Research on Cancer IARC website (Figure 5.11). Mutational analysis was performed on 26 
LSs that over-expressed P53 and were identified at the start of the project. Subsequently 2 
more cases were identified, but not sequenced as the data would not have changed the 
overall conclusion of this part of the thesis. 
The clinical follow up of the 26 cases averaged between 22 and 64 months with a median of 
47.5 months. All cases remained in regular follow up until January 2014 by LTHT. No 
evidence of recurrence or distant metastasis was detected in any of these cases. While the 
presence of the detected P53 mutations did not seem to have influenced the prognosis of 
these cases, due to the limited numbers of cases and the relatively limited follow up period, 
a firm conclusion cannot be made. 
5.6.1 Phenotypical Consequences of the Detected P53 Somatic Mutations  
The Ser46Phe missense mutation in the N-terminus domain of P53 was previously reported 
in urinary bladder (208) and lymphoid tumours (209). In vitro cell line models have 
demonstrated an increased apoptotic activity of the 46Phe variant compared to the wild 
type protein. Consequently this variant was referred to as “super P53” by Nakamura et al. 
(210). The increased apoptotic activity may be a consequence of the variant P53 protein 
having a higher affinity for the cytoplasmic protein clathrin. This interaction subsequently 
activates P53-dependent promoters of apoptosis and up-regulates the transactivation of 
genes downstream of P53 (211). 
The three other detected somatic missense mutations were all mapped to the DNA-binding 
domain, suggesting a disruption to P53’s ability to correctly bind DNA and therefore 
compromising its functions. Asn131Ser has been reported as a point mutation in 
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hepatocellular carcinoma (212) and breast cancers (213), either as a sole mutation or in 
conjunction with other P53 point mutations. Glu171Lys was reported in multiple 
malignancies including breast (214), pulmonary (215) and gastro-intestinal (216). Studies 
from haematological malignancies confirmed that Glu171Lys-mutant P53 was 
transcriptionally active (217) and gastric tumours with P53 mutations, including Glu171Lys, 
were found to over-express cyclo-oxygenase2 and had poorer prognosis (218). Asp184Asn 
was detected in two cases in the study cohort and has previously been reported in multiple 
malignancies including lymphomas (219); colorectal (220); and cervical tumours (221). The 
structure of the mutant P53 protein is not thought to be disrupted, but this mutation is 
believed to affect the sequence-specific binding of P53 to DNA (222). 
The Leu257Gln variant was detected in 2 DDLSs, 1 MXLS, 1 WDLS and 1 control lipoma. In 
the WDLS case, this variant was found in conjunction with other pathological P53 mutations 
(Glu171Lys, Asn131Ser). Leu257Gln is a relatively rare variant of uncertain clinical 
significance, which has been described sporadically. It was reported in early-stage colon 
cancer without lymph node or metastatic involvement (223), in carcinoma in situ of the 
urinary bladder (224), and it was found to have no dominant negative effect in oral cancers 
(225). While the Gln257 variant was reported to retain wild type P53 functions, it was also 
suggested that it may interfere with P53 overall activity (226). Additionally, Gln257 was 
reported to interact normally with MDM2 (227). As Leu257Gln was detected in the control 
subcutaneous lipoma that did not over-express P53, it was therefore reasonable to assume 
that this variant did not affect the P53 expression profile.  
The described frame shift mutation in this study (Lys292*FS) has not previously been 
reported in STS or any other cancers according to IARC TP53 database. However, a sequence 
variant at position c.874A>T in the same codon was reported to result in nonsense mutation 
and a non-functional P53 (228). It is expected therefore that a frame shift at this position 
would have a substantial effect on the resultant protein’s structure and function, since all 
subsequent amino acids are replaced by 10 novel amino acids (ASPRAAPREH*). 
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5.6.2 Significance of P53 Arg72Pro Polymorphism 
Genotyping of the Arg72Pro polymorphism in this study detected the Pro72 variant in 42% 
of cases, whereas a previous study including 35 LSs from the Norwegian patients identified 
the Pro72 variant in 62% of tumours (82). It is possible that the difference in the variant’s 
frequency is due to the small size of each tumour cohort. However, it may also reflect 
differences in the allele frequency between the English and Norwegian populations. The 
frequency of Pro72 allele in the general population germ line ranges from 70% in Africans to 
23% among Western Europeans (229). 
Arg72Pro polymorphism has been extensively reported in different cancers. It appears that 
patients with homozygous and heterozygous Pro72 variant had increased resistance to 
conventional chemotherapy and shorter progression free survival rates in non-small cell 
lung cancer (230) and advanced gastric cancers (231). On the other hand, the germ line 
Pro72 allele has not been associated with increased cancer susceptibility. On the contrary, 
germline homozygous and heterozygous Pro72 individuals were found to have increased 
longevity in human population studies (232, 233). Such discrepancy in prognosis between 
the polymorphism in normal compared to tumour tissue may be explained by the superior 
ability of the Arg72 variant to induce apoptosis, whereas Pro72 variant induces G1 arrest 
and is better at promoting P53-dependent DNA repair (233). 
The two cases that displayed homozygous Pro polymorphism at codon 72 were found to 
have concomitant pathological mutations in the neighbouring exon 5: Glu171Lys and 
Asn131Ser in case no. WD28; and Asp184Asn in case no. WD42. In fact, 4 of the 5 detected 
mutations occurred in tumours carrying the proline-variant (adding cases MR8 and WD39). 
While the numbers in this study are too small to draw a valid conclusion about a correlation 
between P72 and a higher incidence of associated P53 mutations, this finding may be 
important when taking into account the low prevalence of P53 mutations in LSs, in general 
(approximately 20%). In agreement with this finding, Ohnstad et al. reported 48% of mutant 
P53 (n=27), in a series of STSs, to have the Pro72 variant (82). Collectively, these findings 
emphasise the importance of examining the full length of P53 for mutations when 
conducting studies that focus on Arg72Pro polymorphism. 
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5.6.3 P53 Mutations in Relation to the Protein Expression Profiles 
Screening P53 for somatic and germline sequence variants in the cohort of P53 over-
expressing LSs revealed a P53 somatic mutation incidence of 19% (n=5). If we assumed that 
the 3 cases which partially failed PCR amplification for exon 7 harboured a devastating 
mutation in exon 7, then the number of cases will rise to 6 as two of the these cases were 
already found to have mutations in exon 4 and 5 (case numbers MR1 and MR8, 
respectively). Additionally, on the assumption that the two P53 over-expressing cases that 
presented later in the study, and therefore were not subjected to genomic analysis of P53, 
were subsequently found to have a P53 mutation, then the total incidence of P53 mutation 
will rise to 28% (n=8 of 28 new total). These incidences remain within the expected range of 
P53 mutations in LS in general, regardless of their P53 protein expression profile, as 
previously reported in the literature (43, 44). In other words, the majority of LS cases (70 - 
80%) that over-expressed P53 were found to have retained a wild type P53 status.  In turn, 
this suggests that the detected high P53 expression levels were a genuine manifestation of 
the interplay between P53 and its cellular regulators, MDM2 and MDMX. 
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Table 5.1: Summary of P53 somatic mutations in the analysed cohort 
Case no. SNP 72 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8 Exon 9 
DD1 CG       
DD2 GG       
DD3 
GG    
c.770T>A 
(Leu257Gln) 
  
DD4 GG       
DD6 
GG    
c.770T>A 
(Leu257Gln) 
  
DD7 CG       
DD8 GG       
MR1 
GG 
c.137C>T 
(Ser46Phe) 
     
MR2 GG       
MR4 GG       
MR5 GG       
MR6 
GG    
c.770T>A 
(Leu257Gln) 
  
MR7 GG       
MR8 
CG  
c.550G>A 
(Asp184Asn) 
    
MR10 CG       
MR11 CG       
MR12 GG       
WD2 CG       
WD14 CG       
WD28 
CC  
c.511G>A 
(Glu171Lys) 
c.392A>G 
(Asn131Ser) 
 
c.770T>A 
(Leu257Gln) 
  
WD31 CG       
WD36 GG       
WD37 GG       
WD39 
CG     
c.876DelAG 
(Lys292*FS) 
 
WD40 GG       
WD42 
CC  
c.550G>A 
(Asp184Asn) 
    
B1 
Lipoma 
control  
    
c.770T>A 
(Leu257Gln) 
  
Colour key for Table 5.1 
Failed to analyse 
Partially failed to 
analyse 
No mutations 
Non-pathological 
variant 
Pathological 
mutation 
A tabular summary of the detected P53 somatic mutations and SNP variants in the analysed 
cohort. 
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Table 5.2: Characteristics of P53 mutant cases in the analysed cohort 
Case no. Mutation M/F Age Site 
Size 
(cm) 
Histology Cytogenetic 
IHC
 
MDM2 
IHC 
 
MDMX 
IHC 
 
P53 
Follow 
up† 
(months) 
Signific
ant 
events§ 
MR1 Ser46Phe M 70 Buttock 10*7*5 MXLS t12:16 81 91 18 22 None 
MR8 Asp184Asn F 51 Thigh 20*8*8 MXLS Not done 99 46 70 54 None 
WD28 
Asn131Ser 
Glu171Lys 
M 72 Thigh 26*23*11 WDLS 
MDM2 
amplification 
by FISH 
2 8 12 64 None 
WD39 Lys292*FS F 53 Arm 5*3*2 
WDLS 
inflamma
tory 
Normal 
Karyotype by 
G-band 
70 80 32 41 None 
WD42 Asp184Asn F 85 Leg 6*6*3 WDLS 
MDM2 not 
amplified by 
FISH 
84 70 62 33 None 
A tabular summary of the clinical, histological and molecular characteristics of LSs with detectable P53 somatic mutation(s). †clinical follow up is based 
on clinician correspondence and data available from PPM; § Significant events included recurrence, distant metastasis or death.
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Figure 5.1: Agarose gel confirmation of genomic DNA extraction 
Example of ethidium bromide-stained 1% agarose gel electrophoresis of DNA extraction for 
samples 1-10 (as numbered). Samples 5 and 9 were consequently repeated due to poor yield. L1 = 
ladder 1 (1kb ladder); L2 = ladder 2, Lambda DNA/Hind III Marker. 
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Figure 5.2: Agarose gel electrophoresis of PCR products for P53 exon 5 
Example of post-PCR agarose gel electrophoresis for P53-exon 5, samples 1-26 (as numbered). C1 = 
Control1, DNA control from human blood; C2 = Control 2, DNA extraction from a lipoma sample; 
C3 = Control 3, pure H2O negative control; L = ladder, Gene ruler 100bp. 
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Figure 5.3: Agarose gel electrophoresis of post PCR purification products for P53 exon 4 
Example of post PCR purification agarose gel electrophoresis of P53-exon 4, samples 1-26 (as 
numbered). L = ladder, Gene ruler 100bp. 
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Genotype Electropherogram  
P53, exon 4 
Ser46Phe 
c.137C>T 
Case MR1  
 
P53, exon 4 
c.137Wt 
Normal 
control  
Case MR10 
 
Figure 5.4: Electrpherogram of sequence surrounding codon 46 demonstrating Ser46Phe 
Electropherogram of P53 exon 4 representing a heterozygous mutation C>T at residue 173 in case 
MR1 (top), in comparison to case MR10 as a control (bottom). The upper nucleotide sequence 
represents the sample’s sequence while the lower two sequences identify the reference 
nucleotide and amino acid sequences respectively.  Letter codes follow the International Union of 
Pure and Applied Chemistry (IUPAC) coding (Y = C+T). Wt=wild type. 
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Genotype Electropherogram  
P53, exon 5 
c.392A>G 
Asn131Ser 
Case WD28 
 
P53, exon 5 
c.392Wt 
Normal 
control  
Case DD1 
 
Figure 5.5; Electropherogram of sequence surrounding codon 131 demonstrating 
Asn131Ser 
Electropherogram of P53 exon 5 representing a heterozygous mutation A>G at residue 392 in case 
WD28 (top), in comparison to case DD1 as a control (bottom). The upper nucleotide sequence 
represents the sample’s sequence while the lower two sequences identify the reference 
nucleotide and amino acid sequences respectively. Letter codes follow the International Union of 
Pure and Applied Chemistry (IUPAC) coding (R = A+G). Wt = wild type. 
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Genotype Electropherogram  
P53, exon 5 
c.511G>A 
Glu171Lys 
Case WD28 
 
P53, exon 5 
c.511Wt 
Normal 
control  
Case DD1 
 
Figure 5.6: Electropherogram of sequence surrounding codon 171 demonstrating 
Glu171Lys 
Electropherogram of P53 exon 5 representing a heterozygous mutation G>A at residue 511 in case 
WD28 (top), in comparison to case DD1 as a control (bottom). The upper nucleotide sequence 
represents the sample’s sequence while the lower two sequences identify the reference 
nucleotide and amino acid sequences respectively. Letter codes follow the International Union of 
Pure and Applied Chemistry (IUPAC) coding (R = A+G). Wt = wild type. 
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Genotype Electropherogram  
P53, exon 5 
c.550G>A 
Asp184Asn 
Case MR8 
 
P53, exon 5 
c.550G>A 
Asp184Asn 
Case WD42 
 
P53, exon 5 
c.550WT 
Normal 
control  
Case WD40 
 
Figure 5.7: Electropherogram of sequence surrounding codon 184 demonstrating 
Asp184Asn 
Electropherogram of P53 exon 5 representing a heterozygous mutation G>A at residue 550 in 
cases MR8 and WD42 (top2), in comparison to case WD40 as a control (bottom). The upper 
nucleotide sequence represents the sample’s sequence while the lower two sequences identify 
the reference nucleotide and amino acid sequences respectively. Letter codes follow the 
International Union of Pure and Applied Chemistry (IUPAC) coding (R = A+G). Wt = wild type. 
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Genotype Electropherogram  
P53, exon 7 
c.876_877delAG 
Lys292*FS 
Case WD39 
 
P53, exon 7 
c.876Wt 
Normal control  
Case DD1 
Figure 5.8: Electropherogram of sequence surrounding codon 292 demonstrating frame 
shift Lys292 
Electropherogram of P53 exon 8 representing a frame shift resulting from AG deletion at residue 
876-877 in case WD39 (top) in comparison to case DD1 as a control (bottom). The upper 
nucleotide sequence represents the sample’s sequence while the next  two sequences identify the 
reference nucleotide and amino acid sequences respectively. The sequences in the blue bar again 
show the reference sequence while the sequence in the green bar shows the deduced sequence of 
the allele containing the deletion. It can be seen that the deduced sequence is transposed two 
positions 5’of the AG deletion. Due to the presence of the four consecutive G residues at and 3’ to 
the deletion’s location, it only manifests itself as changes in the peak heights these residues.  
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Genotype Electropherogram  
P53, exon 7 
c.770T>A 
Leu257Gln 
Case MR6 
 
P53, exon 7 
c.770T>A 
Leu257Gln 
Case B1 
(lipoma) 
 
P53, exon 7 
c.770Wt 
Normal 
control  
Case DD4 
 
Figure 5.9: Electropherogram of sequence surrounding codon 257 demonstrating 
Leu257Gln 
Electropherogram of P53 exon 7 representing a heterozygous mutation T>A at residue 770 in cases 
MR6 and B1 (top2) as a demonstrative example, in comparison to case DD4 as a control (bottom).  
The upper nucleotide sequence represents the sample’s sequence while the lower two sequences 
identify the reference nucleotide and amino acid sequences respectively. Letter codes follow the 
International Union of Pure and Applied Chemistry (IUPAC) coding (W = A+T). Wt = wild type. 
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Genotype  Electropherogram P53, exon 4  
GG 
homozygous 
Example : 
Case DD2 
 
GC 
heterozygous 
Example : 
Case MR10 
 
CC 
homozygous 
Example: 
Case WD42 
 
Figure 5.10: Electropherogram of sequence surrounding codon 72 demonstrating Arg72Pro 
polymorphism 
Electropherogram of P53 exon 4 representing SNP polymorphism at codon 72. GG homozygous 
resulting in Arginine variant, example case DD2 (top); GC heterozygous resulting in Arginine 
Proline variant, example case MR10 (middle); and CC homozygous resulting in Proline variant, 
example case WD42 (bottom). The upper nucleotide sequence represent the sample’s sequence 
while the lower two sequences identify the reference nucleotide and amino acid sequences 
respectively.   
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Figure 5.11 P53 structure and detected mutations  
A schematic presentation of P53 and the frequency of detected mutations in cancers in general as 
per IARC TP53 database. The green arrows indicate the start and end of the sequenced area of 
P53. Detected mutations are indicated by the red arrows. TAD = Transactivation domain; TD = 
Tetramerisation domain; NES = nuclear export signal; NLS = nuclear localisation signal; aa = amino 
acid. Adopted from WA Freed-Pastor et al., 2013 (54). 
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6 Other Soft Tissue Sarcomas and Benign Tumours 
6.1 Aim 
The aim of this Section is to examine a complementary small cohort of STSs (other than LSs) 
and benign lipomas to assess if they displayed cellular expression profiles of MDM and P53 
proteins that were in line with the observed trends in the LS cohort. 
This complementary cohort consisted of:  
A) Malignant tumours: 3 angiosarcomas and 1 inflammatory fibroblastic tumour  
B) Benign tumours: 3 lipomas, 1 leiomyoma and 1 intramuscular myxoma 
The samples were processed and analysed using identical protocols to those employed in 
the analysis of the LS cohort. 
6.2 Cytogenetics  
Diagnostic cytogenetic analysis was performed in 4 of the 9 cases in the cohort, as a 
consequence of the tumours’ appearances at the time of surgery. In the malignant cases, 
the 3 angiosarcomas were not analysed by FISH as LS was not initially suspected on clinical 
or radiological grounds. However, the inflammatory fibroblastic tumour was found to have 
MDM2 amplification by FISH analysis. In the benign cases, all three benign lipomas were 
negative for MDM2 amplification. The leiomyoma and myxoma cases were not subjected to 
cytogenetic analysis. 
6.3 Immunohistochemistry 
All cases were analysed by IHC and were scored using the same protocols as described 
earlier for the LS cohort. One angiosarcoma over-expressed MDM2 alone (case no. ST1) and 
another over-expressed MDMX alone (case no. ST3). Both cases had low P53 expression. 
However, the third angiosarcoma (case no. ST2) over-expressed all three proteins. In spite of 
a detectable MDM2 amplification, the inflammatory fibroblastic tumour (case no. ST4) 
displayed low MDM2 and P53 protein expression profiles, with moderately over-expressed 
MDMX (+). 
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All three lipomas and the leiomyoma had low expression of MDM2, MDMX and P53. The 
intramuscular myxoma (case no. B5) demonstrated high expression levels (++) of MDM2 and 
MDMX with normal (low) P53 expression profile. 
6.4 Discussion 
6.4.1 Cytogenetic Results  
The absence of MDM2 amplification by the cytogenetic FISH analysis of the three lipomas is 
in agreement with their benign histological evaluation. If the FISH analysis had revealed 
MDM2 amplification in any of these cases, then the histological diagnosis would have been 
reviewed. It may be acceptable to have a histological diagnosis of LS that is not supported 
by MDM2 amplification, but the contrary has not been reported. 
The MDM2 amplification displayed by the inflammatory fibroblastic tumour has been 
previously reported (234). These tumours are extremely rare and would require multicentre 
collaboration to obtain adequate numbers for analysis and characterisation. 
6.4.2 Immunohistochemistry Results  
The expression profile of MDM2 and P53 in the analysed angiosarcomas is consistent with a 
previous analysis that included 19 cases, which revealed that MDM2 and P53 were over-
expressed in 68% and 53% of cases, respectively (235). However, we are not aware of any 
published studies that examined MDMX expression in angiosarcomas. Therefore, our 
observations of possible high frequency of MDMX over-expression in angiosarcomas invite 
further characterisation studies. Similarly, only limited data is available on the expression 
profile of MDM proteins in inflammatory fibroblastic tumours. One study, that included 15 
cases, revealed that approximately 30% of these cancers over-expressed MDM2 (234). 
While there are limited published data on the expression patterns of MDM2, MDMX and 
P53 in these tumour types, our observations of these proteins are in agreement with the 
expression pattern trends described earlier in LSs. The angiosarcoma case that displayed 
(++) profile for both MDM2 and MDMX, additionally over-expressed P53, as seen in the 
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“competitive” pattern; the other 2 angiosarcomas revealed low P53 levels in conjunction 
with a solitary over-expression of MDM2 or MDMX, as seen in the “collaborative” pattern 
(Figure 6.1). These observations are in agreement with the literature, which suggests that 
over-expression of one of the regulatory proteins may be sufficient for P53 inhibition / 
degradation. 
Four of the 5 analysed benign cases displayed immunohistochemical profiles that are within 
the anticipated levels of normal (low) MDM / P53 interaction in non-malignant cells. The 
intramuscular myxoma, on the other hand, had shown high levels of MDM2 and MDMX with 
normal expression of P53. While this expression profile may represent an exception to the 
“competitive” pattern described earlier, such exceptions may be predicted in benign cases. 
A recent review of 11 myxomas did not detect MDM2 amplification in any of these cases 
(236) and no published data regarding MDM2 expression in Intramuscular myxoma was 
found at the time of writing this report. However, it is known that some cells may over-
express MDM2 without gene amplification, as seen within the LS results of this study. 
The different tumours in this complementary cohort displayed a mosaic pattern of co-
expression among the studied proteins, which may emphasise the significance of assessing 
these biomarkers jointly in order to obtain a meaningful picture of their complex 
interactions. It is remarkable how the expression patterns in this small cohort agreed with 
the described interplay between MDM2, MDMX and P53, observed in LSs in this study. 
Therefore, these patterns of protein interaction may represent a general feature of 
malignant cell molecular pathology that is not merely limited to LSs and may be anticipated 
in other cancers. Unfortunately, similar profiling studies in other cancers are lacking. 
 Figure 6.1: P53 expression in relation to Log2(MDM2/MDMX) sc
benign cases 
A scatterplot representing the expression levels of P53 in relation to Log2(MDM2/MDMX) scores. 
A: angisarcoma with (++/++/+) expression profile for (MDM2/MDMX/P53), 
“competitive” interplay pattern; B: 
angiosarcoma and inflammatory fibroplastic tumour with solitary over
the low level of P53 in B and C; D: intra
benign cases retained low levels of activity for P53.
 
 
 
ores in other STS and 
consistent
angiosarcoma with solitary over-expression of MDM2
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7 General Discussion 
7.1 Significance of the Study 
With the emergence of integrated cytogenetic and molecular genetic inputs into the STS 
diagnostics and classification system, a thorough evaluation of the molecular consequences 
of their pathognomonic events should similarly evolve to explore the prospects of future 
novel therapeutic approaches. This makes the MDM2 amplification in LS and its subsequent 
interplay with the tumour suppressor, P53 a very promising area for the development of 
therapeutic agents. 
This study illustrates that the dynamic interactions between MDM proteins and P53 are a 
retained property in LS (and possibly other STS) tissues and does not merely represent a cell 
line observation. These interactions can be effectively assessed with simple, cost-effective 
techniques on FFPE human tissues. Previously, expression profiling of MDM2, MDMX and 
P53 was limited to cell line studies and therefore there were limitations in translating the 
outcomes into clinical use. This study also demonstrated that partial or selective analysis of 
MDM2 or MDMX alongside P53 may result in missing vital information about the 
characteristics of the examined tumours, and therefore may best be avoided. 
The study has revealed that the MDM2 to MDMX ratio is an important factor in the 
expression levels of wild type P53. High P53 levels were seen when MDM2 and MDMX were 
equally over-expressed suggesting a possible competition between the two negative 
regulators to bind to P53 and therefore resulting in reduced P53 degradation. Conversely 
predominant MDM2 over-expression in relation to MDMX resulted in diminished levels of 
P53, suggesting a collaborative effort between MDM2 and MDMX to degrade P53. While 
the detected P53 may be functionally inactivated by the MDM2 and MDMX interactions, 
P53’s activity may be rescued by the use of novel MDM2, MDMX and P53 binding 
antagonists. The conclusions of this study may give greater insight into the selection of 
antagonist drugs in future clinical trials exploring mechanisms to normalise the activity of 
wild type P53 in MDM2 and MDMX over-expressing tumours. 
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7.1.1 Role in Diagnostics 
The results of this study, as well as other related previous analyses (as shown in Table 4.4) 
confirm clear superiority of molecular genetic testing as a diagnostic tool in LSs and STSs in 
general, compared to IHC testing. On the other hand, the IHC characterisation of LSs may 
provide an additional aid in the diagnostic toolkit, especially in cases where cytogenetic and 
molecular genetic assessments are not feasible or are inconclusive. 
7.1.2 Role in Therapeutic Applications 
Early STS cell line studies, which assessed the therapeutic response to a targeted MDM2 
antagonist, utilising Nutlin-3a, have revealed a superior response in cell lines with MDM2 
gene amplification (162, 188). Since then, MDM2 amplification has been considered the 
“benchmark” test to select cases for P53- MDM2 blocking trials. However, it is known that 
MDM2 amplification and over-expression are not always correlated. As the novel blocking 
compounds interact with their targets at the protein-protein level, it may be inappropriate 
to solely adopt the gene amplification status as a predictor of response to this therapeutic 
approach. In addition, selecting cases based solely on their MDM2 status ignores the other, 
equally relevant, regulators of P53 and their role in the complex interplay of manipulating 
P53 cellular abundance and activity. An example of the complexity of the regulation of P53 
activity was provided by Hu et al. , in their description of increased MDMX levels when 
treating MDM2 and MDMX positive cells with Nutlin-3a (164). 
The earliest, proof of principle, clinical trial targeting MDM2-amplified WDLS and DDLS with 
the new generation of Nutlins (RG7112) has revealed disappointing results, with partial 
response in only one of the twenty recruited patients (163). Unfortunately, the study relied 
on the MDM2 amplification status as a benchmark for selecting candidates and ignored the 
relevant MDMX role in the interaction. In light of the findings of this study, it would have 
been interesting to examine the MDM2, MDMX and P53 expression status in all these cases. 
Targeting P53-MDM2 interaction in cases that co-expressed MDMX may merely free P53 
from one inhibitor (MDM2) to attach to another (MDMX), especially since Nutlins are known 
to have very poor affinity for MDMX.  
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It was not until very recently that the use of MDM2 amplification as a benchmark test and a 
predictor of outcomes from Nutlin treatment was criticized, prompting the search for 
alternatives that recognised a holistic approach in the characterisation of candidate tumours 
for selective P53-MDM2 blocking trials (237). However, the majority of subsequent studies 
have failed to recognise the pivotal role of MDMX in P53 regulation. To date, the published 
results of this study represent the only call for simultaneous characterisation of MDM2, 
MDMX and P53, as a potential benchmark test for P53-MDM proteins antagonists (238). 
In summary, cytogenetic and molecular genetic analysis is a key component in the diagnosis 
and classification of STSs, but it may not provide sufficient insights to be the selection 
criterion for targeted P53-MDM blocking therapies. This study proposes that IHC based 
characterisation of LSs may provide additional meaningful interpretation of cellular P53 
availability and may guide the selection of single and /or dual affinity P53-MDM blocker 
compounds in future clinical trials. 
7.2 Limitations of the Study 
Similar to previous STSs studies, or any other rare cancers, concerns may be raised due to 
the sample size and the heterogeneity of the analysed tumour cohort, to reliably represent 
the disease as seen in the clinic. Typically, similar tumour profiling studies, examining other 
more common tumours, would probably involve more cases than used in this study. 
However, the study’s final sample size was comparable to many other related analyses of 
similar rare tumour types and was sufficiently large to provide statistically-significant 
results.  
As discussed in Chapter Four, and in contrast to the majority of cancers, STSs consist of a 
wide variety of tumour types resulting in a multifaceted classification system. Even the 
simple distinction between benign and malignant tumours in soft tissue neoplasms may 
occasionally prove to be extremely challenging and occasionally interpreter-dependent. This 
in turn, may provide a source of confusion and lack of consistency that may introduce 
classification errors in large, multi-centric trials or in literature reviews, where apparent 
homogenous tumour cohorts are in fact more heterogeneous than believed. However, one 
could hope that the introduction of the new WHO classification and the introduction of 
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molecular genetic based testing into STS tumour typing, may create a uniform mechanism 
towards a more objective, meaningful and synonymous categorisation for STSs, including 
the most challenging clinical cases.  
7.3 Future Perspectives 
To translate the findings of this study into the clinic, it will be necessary to conduct 
functional studies to evaluate the pharmacological effects of single and dual affinity blocking 
compounds in LSs, in light of their IHC profiles. Functional assessments have become 
increasingly important and clinically relevant with the advent of new MDM2 / MDMX 
blocking compounds of variable affinities. As some of these compounds are in phase I and 
phase II clinical trials, it is certainly vital to establish clear guidance for effective candidate 
selection with selective antagonist drug matching to these candidates. It is equally relevant 
to seek reliable predictors of outcome to further guide clinical trials. 
Therefore, we propose functional studies utilising the Tissue Explant System introduced by 
Singh et al. (239) and later modified by Pishas et al. for the purpose of STS experiments 
(237). The system is designed to grow 1 mm
3
 pieces of freshly excised STS on a dental 
sponge immersed in a cocktail of RPMI media with 5% foetal bovine serum and other 
reagents. The tissue blocks can then be incubated with the drug of choice or a suitable 
control, at 37˚C in a humidified atmosphere for a period of 48 hrs. Subsequently, tissue 
pieces may be harvested and evaluated for cellular activity, apoptosis, activity of P53 and its 
downstream pathways and any other parameters that may be relevant to objectively 
quantify the desired pharmacological response. 
This proposed model of experiment may provide quantitative assessments as to the efficacy 
of different lead MDM blocking compounds. It may clarify the potential utility, and putative 
superiority, of dual MDM2 / MDMX blocking compounds, compared to single affinity MDM2 
blockers, in cases that over-express both proteins by IHC. In addition, the alleged synergistic 
effect, obtained by adding conventional chemotherapy agents to MDM blockers can be 
scrutinised and detailed. Collectively, functional studies of this kind may provide a promising 
experimental platform for future clinical trials. 
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Finally, LSs are excellent candidates for targeted therapies of this pathway, as they mainly 
retain a wild type status of P53 and demonstrate MDM2 amplification / over-expression in 
the majority of cases. Moreover, this promising approach of P53 reactivation is not limited 
to a certain subset of tumours and it may be applicable to a wide range of cancers after 
careful characterisation of their relevant MDM biomarkers. 
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II- List of Abbreviations 
aa   Amino Acid 
Ab(s)   Antibodies 
ARF   Alternative Reading Frame 
Arg   Arginine 
Asn    Asparagine 
Asp   Aspartic acid 
ATCC
®
   American Type Culture Collection 
bp   Base Pair 
BCA   Bicinchoninic Acid Assay 
BSA   Bovine Serum Albumin 
CGH   Comparative Genomic Hybridisation  
DAPI   4',6-diamidino-2-phenylindole 
dATP   Deoxyadenosine Triphosphate  
dCTP   Deoxycytidine Triphosphate 
DDLS   De-differentiated Liposarcoma 
dGTP   Deoxyguanosine Triphosphate 
DTT   Dithiothreitol  
DMEM   Dulbecco's Modified Eagle’s Medium 
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic Acid 
dNTP   Deoxynucleoside Triphosphates 
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DPBS   Dulbecco's Phosphate-Buffered Saline 
dTTP   Deoxythymidine Triphosphate 
EDTA   Ethylene di-amine tetra-acetic acid disodium salt 
FCS   Foetal Calf Serum 
FFPE   Formalin-Fixed Paraffin-Embedded 
FISH    Fluorescence in situ Hybridization 
Gln   Glutamine 
Glu   Glutamic acid 
HiDi   Highly Deionised 
hr(s)   Hour(s) 
HRP   Horseradish Peroxidase 
IAPs    Inhibitor of Apoptosis Proteins 
ICC   Immunocytochemistry 
IHC   Immunohistochemistry 
IARC   International Agency for Research on Cancer 
IUPAC   International Union of Pure and Applied Chemistry 
Kb   kilobase-pairs 
KDa   Kilo Dalton  
LDS   Lithium Dodecyl Sulphate 
Leu   Leucine 
LIMM   Leeds Institute of Molecular Medicine 
LS(s)   Liposarcoma(s) 
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LTHT   Leeds Teaching Hospitals NHS Trust 
Lys   Lysine 
M   Molar 
MDM   Murine Double Minute 
MFH   Malignant Fibrous Histiocytoma 
mg   milligram  
ml   millilitre 
mM   millimolar 
nM   nanomolar 
MXLS   Myxoid Liposarcoma 
NCIN   National Cancer Intelligence Network 
ND   Not Done 
NES   Nuclear Export Signal 
NLS   Nuclear Localisation Signal 
ng   nanogram  
nm   nanometre  
NoLS   Nucleolar Localisation Signal 
NP-40   Nonyl phenoxypolyethoxylethanol 
PCR   Polymerase Chain Reaction 
Phe   Phenylalanine 
pM   picomolar 
PMSF   Phenylmethanesulfonyl Fluoride 
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PPM   Patient Pathway Manager 
Pro   Proline 
RCLS   Round Cell Liposarcoma   
RING   Really Interesting New Gene  
RIPA   Radioimmunoprecipitation Assay 
RPMI   Roswell Park Memorial Institute 
SC   Spindle Cell 
SDS   Sodium Dodecyl Sulphate 
Ser   Serine 
StR   Speciality Training Registrar  
STS(s)   Soft Tissue Sarcoma(s) 
TAD   Transactivation Domain 
TBS   Tris-Buffered Saline 
TD   Tetramerisation Domain 
UK   United Kingdom 
UCSC   University of California, Santa Cruz 
v/v   volume/volume 
v/w   volume/weight 
WDLS   Well-Differentiated Liposarcoma  
WHO   World Health Organisation 
Wt   Wild Type  
Zn   Zinc 
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µg   micrograms 
µl   microlitres 
µM   micromolar 
µm   micrometre 
°C   degrees Celsius  
+ve   positive 
-ve   negative 
  
 155 
 
III- Appendices 
List of Appendices:  
1- Ethical Approval Letter and LTHT Research and Development Approval 
2- Participants Information Sheet and Consent Form  
3- Full Cohort of Study Participants 
  
 156 
 
1- Ethical Approval Letter and Leeds Teaching Hospital Trust 
Research and Development Approval  
  
 157 
 
 158 
 159 
 160 
 
 
  
 161 
 
 
 162 
 
 163 
 
2- Participant Information Sheet and Consent Form  
 164 
 
 165 
 
 166 
 
 167 
 
 168 
 
  
 169 
 
3-Full Cohort of Study Participants 
 
 
 
 
 
 
 
 
 
Full Participants Cohort – WDLS 
170 
Case 
no. 
Gender Age Site Size (cm) Histology Grade 
Cytogenetic 
results 
Fresh 
sample 
IHC score 
P53 mutation 
MDM2 MDMX P53 
WD1 F 85 Thigh (left) 14*13*3 WD LS 1 Failed N 42 5 1 ND 
WD2 M 65 Arm (right) 8*6*2 WD LS 1 Failed N 99 85 63 None 
WD3 F 74 Thight (right) 19*16*10 WD LS 1 Failed N 98 14 2 ND 
WD4 F 72 Back 4*4*3 WD LS 1 MDM2 Amp N 76 1 8 ND 
WD5 F 45 Back 26*20*4 WD LS 1 MDM2 Amp N 7 2 1 ND 
WD6 F 65 Forearm (left) 14*6*4 WD LS 1 MDM2 Amp N 2 1 1 ND 
WD7 F 66 Retroperitoneal 40*35*10 WD LS 2 MDM2 Amp Y 56 37 3 ND 
WD8 F 60 Retroperitoneal 35*17*16 WD LS 1 MDM2 Amp N 92 4 2 ND 
WD9 F 40 Retroperitoneal 9*6*4 WD LS 1 MDM2 Amp Y 65 15 1 ND 
WD10 F 73 Shoulder (right) 16*7*4 WD LS 1 MDM2 Amp N 2 2 1 ND 
WD11 F 63 Thigh (left) 29*12*7 WD LS 1 MDM2 Amp N 92 21 1 ND 
WD12 F 74 Thigh (left) 8*10*5 WD LS 1 MDM2 Amp N 42 14 2 ND 
WD13 F 64 Thigh (right) 18*15*4 WD LS 1 MDM2 Amp N 37 16 2 ND 
WD14 F 78 Thigh (right) 14*10*10 WD LS 1 MDM2 Amp N 68 60 25 None 
WD15 F 56 Thigh (right) 17*12*4 WD LS 1 MDM2 Amp N 43 40 4 ND 
WD16 F 67 Thigh (right) 19*17*6 WD LS 1 MDM2 Amp N 30 11 1 ND 
WD17 F 47 Thigh (right) 21*14*5 WD LS 1 MDM2 Amp N 69 64 1 ND 
WD18 F 56 Thigh (right) 11*8*5 WD LS 1 MDM2 Amp N 26 5 1 ND 
WD19 F 60 Thight (left) 20*15*4 WD LS 1 MDM2 Amp N 32 18 7 ND 
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Case 
no. 
Gender Age Site Size (cm) Histology Grade 
Cytogenetic 
results 
Fresh 
sample 
IHC score 
P53 mutation 
MDM2 MDMX P53 
WD20 F 66 Retroperitoneal 27*11*9 WD LS 1 MDM2 Amp Y 47 56 36 None 
WD21 F 49 Retroperitoneal 12*7*2 WD LS 1 MDM2 Amp Y 15 7 2 ND 
WD22 M 71 Chest wall 9*9*5 WD LS 1 MDM2 Amp N 2 2 1 ND 
WD23 M 69 Chest wall 5*4*2 WD LS 1 MDM2 Amp N 5 2 1 ND 
WD24 M 50 Chest wall 9*7*1 WD LS 1 MDM2 Amp N 6 4 1 ND 
WD25 M 58 Gluteal (right) 25*17*5 WD LS 1 MDM2 Amp N 67 30 2 ND 
WD26 M 68 Retroperitoneal 21*15*4 WD LS 1 MDM2 Amp N 19 1 1 ND 
WD27 M 63 Thigh (left) 30*19*15 WD LS 1 MDM2 Amp N 33 1 2 ND 
WD28 M 72 Thigh (right) 26*23*11 WD LS 1 MDM2 Amp N 2 8 12 
Glu171Lys 
Asn131Ser 
WD29 M 64 Thigh (right) 21*11*3 WD LS 1 MDM2 Amp N 53 28 4 ND 
WD30 M 44 Gluteal (left) 9*7*5 WD LS 1 MDM2 Amp N 99 85 29 Failed Ex7 
WD31 M 77 Thigh (left) 15*12*3 WD LS 1 MDM2 Amp N 95 5 2 ND 
WD32 M 83 Thigh (right) 28*26*12 WD LS 1 MDM2 Amp N 98 14 6 ND 
WD33 M 62 Pericardial 18*18*10 WD LS 1 MDM2 Amp N 7 2 1 ND 
WD34 M 71 Retroperitoneal 12*10*9 
WD LS -
Mixed 
1 MDM2 Amp Y 43 41 39 None 
WD35 F 67 Thigh (right) 12*10*2 WD LS 1 
MDM2 Amp - G 
band normal 
N 76 63 2 ND 
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Case 
no. 
Gender Age Site Size (cm) Histology Grade 
Cytogenetic 
results 
Fresh 
sample 
IHC score 
P53 mutation 
MDM2 MDMX P53 
WD36 F 59 Thigh (left) 11*4*3 WD LS 1 
MDM2 Amp   
G band normal 
N 3 5 98 None 
WD37 M 67 Thigh (left) 14*8*7 WD LS 1 
MDM2 Normal  
13q deletion 
N 25 5 46 None 
WD38 M 62 Thigh (right) 15*10*3 WD LS 1 
MDM2 Normal  
13q monosomy 
N 80 32 6 ND 
WD39 F 53 Arm (right) 5*3*2 
WD LS – 
inflammatory 
2 
MDM2 Normal  
G band normal 
N 70 80 32 Lys292*FS 
WD40 M 61 
Chest wall 
(right) 
4*2*2 WD LS 1 
MDM2 Normal  
G band normal 
N 95 85 67 None 
WD41 F 73 Leg (left) 10*10*6 WD LS 1 
MDM2 Normal 
Gain Ch12 
N 32 18 1 ND 
WD42 F 85 Leg (right) 6*6*3 WD LS 1 
MDM2 Normal  
13q monosomy 
N 84 70 62 Asp184Asn 
WD43 M 73 Thigh (right) 9*6*4 WD LS 1 Not Done N 3 2 1 ND 
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Case 
no. 
Gender Age Site Size (cm) Histology Grade Cytogenetic results 
Fresh 
sample 
IHC score P53 
mutation MDM2 MDMX P53 
DD1 M 70 Back 19*10*4 DD LS 3 
G band uncertain 
findings 
N 32 62 79 None 
DD2 M 62 Chest wall (right) 19*19*3 DD LS 3 
MDM2 Amp 
G band normal 
N 98 25 95 None 
DD3 F 78 Retroperitoneal 20*18*8 DD LS 2 MDM2 Amp Y 92 78 18 Leu257Gln 
DD4 F 38 Retroperitoneal 20*18*18 DD LS 2 MDM2 Amp N 41 52 15 None 
DD5 M 63 Retroperitoneal 40*35*12 DD LS 2 MDM2 Amp N 92 28 2 ND 
DD6 M 65 Retroperitoneal 29*24*14 DD LS 3 MDM2 Amp N 58 60 52 Leu257Gln 
DD7 M 69 Retroperitoneal 25*20*14 DD LS 3 MDM2 Amp Y 98 95 72 None 
DD8 M 73 Retroperitoneal 23*20*8 DD LS 3 
MDM2 Amp 
G band normal 
N 97 70 52 None 
DD9 F 64 Retroperitoneal 15*15*4 DD LS 3 Not attempted N 41 31 1 ND 
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Case 
no. 
Gender Age Site Size (cm) Histology Grade Cytogenetic results 
Fresh 
sample 
IHC score P53 
mutation MDM2 MDMX P53 
MR1 M 70 Buttock (left) 10*7*5 MXLS 1 12:16 Translocation N 81 91 18 Ser46Phe 
MR2 M 47 Knee (right) 6*6*4 MXLS 3 12:16 Translocation N 76 90 42 None 
MR3 F 48 Thigh (left) 18*13*7 MXLS 1 
CHOP 
rearrangement 
N 88 98 2 ND 
MR4 M 37 Thigh (left) 8*7*5 MXLS 3 
CHOP 
rearrangement 
N 50 75 27 None 
MR5 M 44 Pelvic 17*11 MXLS 1 
CHOP 
rearrangement 
N 97 99 80 None 
MR6 M 64 Chest wall (left) 9*7* MXLS 2 
Complex multiple 
translocations 
N 98 87 52 Lue257Gln 
MR7 F 53 Thigh (left) 6*6 MXLS 2 Not attempted N 90 84 36 None 
MR8 F 51 Thigh (left) 20*8*8 MXLS 2 Not attempted N 99 46 32 Asp184Asn 
MR9 M 44 Retroperitoneal 24*20 MXLS 2 
Possible MDM2 
Amp 
N 1 2 1 ND 
MR10 M 54 Thigh (left) 23*19*18 MXLS RCLS 3 12:16 Translocation N 14 86 18 None 
MR11 F 44 Thigh (left) 3*2*2 RCLS 3 12:16 Translocation N 54 95 27 None 
MR12 F 38 Thigh (right) 18*13*12 RCLS 3 Failed N 92 90 72 None 
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Amp = Amplification; IHC = Immunohistochemistry; ND = Not Done; no. = number. 
Case 
no. 
Gender Age Site Size (cm) Histology Cytogenetic 
results 
Fresh 
sample 
IHC score P53 
mutation MDM2 MDMX P53 
ST1 F 77 Chest wall 2.5 Angiosarcoma ND Y 17 6 3 ND 
ST2 F 74 Breast 4 Angiosarcoma ND Y 39 44 70 ND 
ST3 F 41 Breast unknown Angiosarcoma ND Y 5 24 6 ND 
ST4 F 51 Retroperitoneal 17*12*14 Inflammatory fibroblastic tumour MDM2 Amp Y 3 12 8 ND 
B1 F 31 Pelvic 9*8*3 Lipoma MDM2 Normal Y 6 3 2 None 
B2 M 46 Axilla 5*4*2 Lipoma MDM2 Normal Y 2 3 5 ND 
B3 M 35 Back 13*11*4 Lipoma MDM2 Normal Y 1 1 1 ND 
B4 F 45 Retroperitoneal 20*14*10 Leiomyoma ND Y 3 1 1 ND 
B5 F 73 Retroperitoneal 13*11*7 Intramuscular Myxoma ND Y 57 68 5 ND 
